Index: /qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID =================================================================== --- /qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID (revision 1508) +++ /qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID (revision 1508) @@ -0,0 +1,3196 @@ +KIDS Distribution saved on Aug 03, 2012@17:09:59 +QUALITY MEASURES 1.0 PATCH 3 +**KIDS**:C0Q*1.0*3^ + +**INSTALL NAME** +C0Q*1.0*3 +"BLD",7936,0) +C0Q*1.0*3^QUALITY MEASURES^0^3120803^y +"BLD",7936,1,0) +^^155^155^3120803^ +"BLD",7936,1,1,0) + Summary +"BLD",7936,1,2,0) + ======= +"BLD",7936,1,3,0) + This build contains the Quality Measures file (#1130580001.101) fully +"BLD",7936,1,4,0) + populated with the Reminder Rule Sets and if applicable Reminder Extract +"BLD",7936,1,5,0) + definitions for use with the Quality Measures package for reporting for +"BLD",7936,1,6,0) + Meaningful use Stage I. +"BLD",7936,1,7,0) + +"BLD",7936,1,8,0) + Source, Copyright, & Licensing: +"BLD",7936,1,9,0) + =============================== +"BLD",7936,1,10,0) + This patch to WorldVistA 2.0 was produced by Sam Habiel on a copy of Dew +"BLD",7936,1,11,0) +Drop and tested on a virgin instance of WV EHR 3-09 patched with PXRM 2.0 +"BLD",7936,1,12,0) +patches 12 and 17. The build was produced in July 2012. +"BLD",7936,1,13,0) + Copyright WorldVistA 2012. +"BLD",7936,1,14,0) + Licensed under GPL version 2 or later. Find it here: +"BLD",7936,1,15,0) +http://www.gnu.org/licenses/gpl-2.0.html +"BLD",7936,1,16,0) + Released through VISTA Forum. +"BLD",7936,1,17,0) + +"BLD",7936,1,18,0) + Functionality: +"BLD",7936,1,19,0) + ============== +"BLD",7936,1,20,0) + This patch is a pure data patch. It only installs reference data in the +"BLD",7936,1,21,0) +C0Q QUALITY MEASURE file (#1130580001.101). It relies on Reminder Package +"BLD",7936,1,22,0) +data (specifically rule sets and extracts) sent in C0Q*1.0*2. +"BLD",7936,1,23,0) + +"BLD",7936,1,24,0) + Package Elements: +"BLD",7936,1,25,0) + ================= +"BLD",7936,1,26,0) + This build transports entries in the C0Q QUALITY MEASURE file. +"BLD",7936,1,27,0) + +"BLD",7936,1,28,0) + Routines: +"BLD",7936,1,29,0) + ========= +"BLD",7936,1,30,0) + +"BLD",7936,1,31,0) + +"BLD",7936,1,32,0) + Documentation: +"BLD",7936,1,33,0) + +"BLD",7936,1,34,0) + +"BLD",7936,1,35,0) + Test Sites: +"BLD",7936,1,36,0) + =========== +"BLD",7936,1,37,0) + +"BLD",7936,1,38,0) + +"BLD",7936,1,39,0) + Compliance: +"BLD",7936,1,40,0) + =========== +"BLD",7936,1,41,0) + This software complies with the VA MUMPS Programming Standards and +"BLD",7936,1,42,0) + Conventions (version 3 April 2007). +"BLD",7936,1,43,0) + +"BLD",7936,1,44,0) + Installation Instructions: +"BLD",7936,1,45,0) + ========================== +"BLD",7936,1,46,0) + Pre-installation: +"BLD",7936,1,47,0) + +"BLD",7936,1,48,0) + Prerequisite patches: (both found on the trac server here: +"BLD",7936,1,49,0) + https://trac.opensourcevista.net/svn/qrda/C0Q/trunk/kids/) +"BLD",7936,1,50,0) + C0Q*1.0*2 +"BLD",7936,1,51,0) + QUALITY MEASURES 1.0 +"BLD",7936,1,52,0) + +"BLD",7936,1,53,0) + Users can remain on the system while this patch is installed. +"BLD",7936,1,54,0) + +"BLD",7936,1,55,0) + Install Time - less than 1 minute. +"BLD",7936,1,56,0) + +"BLD",7936,1,57,0) + 1. LOAD TRANSPORT GLOBAL +"BLD",7936,1,58,0) + +"BLD",7936,1,59,0) + Choose the PackMan message containing this patch and invoke the +"BLD",7936,1,60,0) + INSTALL/CHECK MESSAGE PackMan option to unload the build, or +"BLD",7936,1,61,0) + Use the Load a Distribution option in KIDS to load it from a +"BLD",7936,1,62,0) + host file. +"BLD",7936,1,63,0) + +"BLD",7936,1,64,0) + 2. START UP KIDS +"BLD",7936,1,65,0) + +"BLD",7936,1,66,0) + Start up the Kernel Installation and Distribution System Menu +"BLD",7936,1,67,0) + [XPD MAIN]: +"BLD",7936,1,68,0) + +"BLD",7936,1,69,0) + Edits and Distribution ... +"BLD",7936,1,70,0) + Utilities ... +"BLD",7936,1,71,0) + Installation ... +"BLD",7936,1,72,0) + +"BLD",7936,1,73,0) + Select Kernel Installation & Distribution System Option: INStallation +"BLD",7936,1,74,0) + --- +"BLD",7936,1,75,0) + Load a Distribution +"BLD",7936,1,76,0) + Print Transport Global +"BLD",7936,1,77,0) + Compare Transport Global to Current System +"BLD",7936,1,78,0) + Verify Checksums in Transport Global +"BLD",7936,1,79,0) + Install Package(s) +"BLD",7936,1,80,0) + Restart Install of Package(s) +"BLD",7936,1,81,0) + Unload a Distribution +"BLD",7936,1,82,0) + Backup a Transport Global +"BLD",7936,1,83,0) + +"BLD",7936,1,84,0) + Select Installation Option: +"BLD",7936,1,85,0) + +"BLD",7936,1,86,0) + 3. Select Installation Option: +"BLD",7936,1,87,0) + +"BLD",7936,1,88,0) + NOTE: The following are OPTIONAL - (When prompted for the INSTALL +"BLD",7936,1,89,0) + NAME, enter C0Q*1.0*3): +"BLD",7936,1,90,0) + +"BLD",7936,1,91,0) + a. Backup a Transport Global - This option will create a backup +"BLD",7936,1,92,0) + message of any routines exported with this patch. It will not +"BLD",7936,1,93,0) + backup any other changes such as DD's or templates. +"BLD",7936,1,94,0) + b. Compare Transport Global to Current System - This option will +"BLD",7936,1,95,0) + allow you to view all changes that will be made when this patch +"BLD",7936,1,96,0) + is installed. It compares all components of this patch +"BLD",7936,1,97,0) + (routines, DD's, templates, etc.). +"BLD",7936,1,98,0) + c. Verify Checksums in Transport Global - This option will allow +"BLD",7936,1,99,0) + you to ensure the integrity of the routines that are in the +"BLD",7936,1,100,0) + transport global. +"BLD",7936,1,101,0) + +"BLD",7936,1,102,0) + 4. Select Installation Option: Install Package(s) +"BLD",7936,1,103,0) + +"BLD",7936,1,104,0) + **This is the step to start the installation of this KIDS patch: +"BLD",7936,1,105,0) + +"BLD",7936,1,106,0) + a. Choose the Install Package(s) option to start the patch install +"BLD",7936,1,107,0) + and enter "C0Q*1.0*3" at the INSTALL NAME prompt. +"BLD",7936,1,108,0) + b. When prompted 'Want KIDS to Rebuild Menu Trees Upon Completion of +"BLD",7936,1,109,0) + Install? NO//' answer NO +"BLD",7936,1,110,0) + c. When prompted 'Want KIDS to INHIBIT LOGONs during the install? +"BLD",7936,1,111,0) + NO//' answer NO +"BLD",7936,1,112,0) + d. When prompted 'Want to DISABLE Scheduled Options, Menu Options, +"BLD",7936,1,113,0) + and Protocols? NO//' answer NO +"BLD",7936,1,114,0) + +"BLD",7936,1,115,0) + +"BLD",7936,1,116,0) +Here is an example installation log. +"BLD",7936,1,117,0) +Select INSTALL NAME: C0Q*1.0*3 Loaded from Distribution Loaded +"BLD",7936,1,118,0) +from Di +"BLD",7936,1,119,0) +stribution 8/3/12@16:32:30 +"BLD",7936,1,120,0) + => SDFGHJKL ;Created on Aug 03, 2012@16:31:28 +"BLD",7936,1,121,0) + +"BLD",7936,1,122,0) +This Distribution was loaded on Aug 03, 2012@16:32:30 with header of +"BLD",7936,1,123,0) + SDFGHJKL ;Created on Aug 03, 2012@16:31:28 +"BLD",7936,1,124,0) + It consisted of the following Install(s): +"BLD",7936,1,125,0) + C0Q*1.0*3 +"BLD",7936,1,126,0) + +"BLD",7936,1,127,0) + Checking C0Q*1.0*3 for overlap with VOE 1.0 . OK +"BLD",7936,1,128,0) + No overlap found +"BLD",7936,1,129,0) +DEVICE: HOME// PHOME HOME PRINTER +"BLD",7936,1,130,0) + +"BLD",7936,1,131,0) + +"BLD",7936,1,132,0) + Install Started for C0Q*1.0*3 : +"BLD",7936,1,133,0) + Aug 03, 2012@16:35:24 +"BLD",7936,1,134,0) + +"BLD",7936,1,135,0) +Build Distribution Date: Aug 03, 2012 +"BLD",7936,1,136,0) + +"BLD",7936,1,137,0) + Installing Routines:. +"BLD",7936,1,138,0) + Aug 03, 2012@16:35:24 +"BLD",7936,1,139,0) + +"BLD",7936,1,140,0) + Installing Data Dictionaries: .. +"BLD",7936,1,141,0) + Aug 03, 2012@16:35:24 +"BLD",7936,1,142,0) + +"BLD",7936,1,143,0) + Installing Data: +"BLD",7936,1,144,0) + Aug 03, 2012@16:35:24 +"BLD",7936,1,145,0) + +"BLD",7936,1,146,0) + Updating Routine file..... +"BLD",7936,1,147,0) + +"BLD",7936,1,148,0) + Updating KIDS files....... +"BLD",7936,1,149,0) + +"BLD",7936,1,150,0) + C0Q*1.0*3 Installed. +"BLD",7936,1,151,0) + Aug 03, 2012@16:35:24 +"BLD",7936,1,152,0) + +"BLD",7936,1,153,0) + Not a VA primary domain +"BLD",7936,1,154,0) + +"BLD",7936,1,155,0) + NO Install Message sent +"BLD",7936,4,0) +^9.64PA^1130580001.101^1 +"BLD",7936,4,1130580001.101,0) +1130580001.101 +"BLD",7936,4,1130580001.101,222) +y^y^f^^y^^y^o^n +"BLD",7936,4,"B",1130580001.101,1130580001.101) + +"BLD",7936,6.3) +11 +"BLD",7936,"ABPKG") +n +"BLD",7936,"KRN",0) +^9.67PA^779.2^20 +"BLD",7936,"KRN",.4,0) +.4 +"BLD",7936,"KRN",.401,0) +.401 +"BLD",7936,"KRN",.402,0) +.402 +"BLD",7936,"KRN",.403,0) +.403 +"BLD",7936,"KRN",.5,0) +.5 +"BLD",7936,"KRN",.84,0) +.84 +"BLD",7936,"KRN",3.6,0) +3.6 +"BLD",7936,"KRN",3.8,0) +3.8 +"BLD",7936,"KRN",9.2,0) +9.2 +"BLD",7936,"KRN",9.8,0) +9.8 +"BLD",7936,"KRN",19,0) +19 +"BLD",7936,"KRN",19.1,0) +19.1 +"BLD",7936,"KRN",101,0) +101 +"BLD",7936,"KRN",409.61,0) +409.61 +"BLD",7936,"KRN",771,0) +771 +"BLD",7936,"KRN",779.2,0) +779.2 +"BLD",7936,"KRN",870,0) +870 +"BLD",7936,"KRN",8989.51,0) +8989.51 +"BLD",7936,"KRN",8989.52,0) +8989.52 +"BLD",7936,"KRN",8994,0) +8994 +"BLD",7936,"KRN","B",.4,.4) + +"BLD",7936,"KRN","B",.401,.401) + +"BLD",7936,"KRN","B",.402,.402) + +"BLD",7936,"KRN","B",.403,.403) + +"BLD",7936,"KRN","B",.5,.5) + +"BLD",7936,"KRN","B",.84,.84) + +"BLD",7936,"KRN","B",3.6,3.6) + +"BLD",7936,"KRN","B",3.8,3.8) + +"BLD",7936,"KRN","B",9.2,9.2) + +"BLD",7936,"KRN","B",9.8,9.8) + +"BLD",7936,"KRN","B",19,19) + +"BLD",7936,"KRN","B",19.1,19.1) + +"BLD",7936,"KRN","B",101,101) + +"BLD",7936,"KRN","B",409.61,409.61) + +"BLD",7936,"KRN","B",771,771) + +"BLD",7936,"KRN","B",779.2,779.2) + +"BLD",7936,"KRN","B",870,870) + +"BLD",7936,"KRN","B",8989.51,8989.51) + +"BLD",7936,"KRN","B",8989.52,8989.52) + +"BLD",7936,"KRN","B",8994,8994) + +"BLD",7936,"QUES",0) +^9.62^^ +"BLD",7936,"REQB",0) +^9.611^2^2 +"BLD",7936,"REQB",1,0) +C0Q*1.0*2^2 +"BLD",7936,"REQB",2,0) +QUALITY MEASURES 1.0^2 +"BLD",7936,"REQB","B","C0Q*1.0*2",1) + +"BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2) + +"DATA",1130580001.101,4,0) +PQRI MEASURE 124^^^2.16.840.1.113883.3.249.11.11 +"DATA",1130580001.101,4,1) +Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records +"DATA",1130580001.101,4,4) +PQRI-124 +"DATA",1130580001.101,4,5) +Adoption/Use of Electronic Health Records (EHR) +"DATA",1130580001.101,4,6,0) +^^3^3^3101013^ +"DATA",1130580001.101,4,6,1,0) +Documents whether provider has adopted and is using health inf +"DATA",1130580001.101,4,6,2,0) +ormation technology. To qualify, the provider must havea adopted and be +"DATA",1130580001.101,4,6,3,0) +using a certified/qualified electronic health record (EHR) +"DATA",1130580001.101,4,7) +^^^^ +"DATA",1130580001.101,6,0) +PQRI MEASURE 47^^^2.16.840.1.113883.3.249.11.52 +"DATA",1130580001.101,6,1) +Measure #47: Advance Care Plan +"DATA",1130580001.101,6,4) +PQRI-47 +"DATA",1130580001.101,6,5) +Advance Care Plan +"DATA",1130580001.101,6,6,0) +^1130580001.111^5^5^3101014^^^ +"DATA",1130580001.101,6,6,1,0) +Percentage of patients age 65 and older who have an advanced care plan or +"DATA",1130580001.101,6,6,2,0) +surrogate decision maker documented in the medical record or documented +"DATA",1130580001.101,6,6,3,0) +in the medical record that an advance care plan was discussed but the +"DATA",1130580001.101,6,6,4,0) +patient did not wish or was not able to name a surrogate decision maker +"DATA",1130580001.101,6,6,5,0) +or provide an advance care plan. +"DATA",1130580001.101,6,7) +^^^^ +"DATA",1130580001.101,7,0) +PQRI MEASURE 48^^^2.16.840.1.113883.3.249.11.53 +"DATA",1130580001.101,7,1) +Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older +"DATA",1130580001.101,7,4) +PQRI-48 +"DATA",1130580001.101,7,5) +Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older +"DATA",1130580001.101,7,6,0) +^^3^3^3101013^ +"DATA",1130580001.101,7,6,1,0) +Percentage of patients equal to or older than 65 years of age at the +"DATA",1130580001.101,7,6,2,0) +beginning of the measurement perion who were assesed for the presence or +"DATA",1130580001.101,7,6,3,0) +absence of urinary incontinence within 12 months +"DATA",1130580001.101,7,7) +^^^^ +"DATA",1130580001.101,12,0) +MU EP NQF 0043^^^2.16.840.1.113883.3.249.11.8 +"DATA",1130580001.101,12,1) +Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older +"DATA",1130580001.101,12,4) +PQRI-111 +"DATA",1130580001.101,12,5) +Pneumonia Vaccination for Patients 65 Years and Older +"DATA",1130580001.101,12,6,0) +^1130580001.111^2^2^3120730^^ +"DATA",1130580001.101,12,6,1,0) +Percentage of patients afed 65 years and older who have ever r +"DATA",1130580001.101,12,6,2,0) +eceived a pneumoccal vaccine +"DATA",1130580001.101,12,7) +NQF0043 +"DATA",1130580001.101,14,0) +PQRI MEASURE 39^^^2.16.840.1.113883.3.249.11.51 +"DATA",1130580001.101,14,1) +Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older +"DATA",1130580001.101,14,4) +PQRI-39 +"DATA",1130580001.101,14,5) +Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older +"DATA",1130580001.101,14,6,0) +^^3^3^3101013^ +"DATA",1130580001.101,14,6,1,0) +Percentage of patients who had a DXA measurement ordered or pe +"DATA",1130580001.101,14,6,2,0) +rformed at least once since age 60 or pharmacologic therapy prescribed +"DATA",1130580001.101,14,6,3,0) +within 12 months before the end of the measurement period +"DATA",1130580001.101,14,7) +^^^^ +"DATA",1130580001.101,16,0) +PQRI MEASURE 173^^^2.16.840.1.113883.3.249.11.55 +"DATA",1130580001.101,16,1) +Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening +"DATA",1130580001.101,16,4) +PQRI-173 +"DATA",1130580001.101,16,5) +Preventive Care and Screening: Unhealthy Alcohol Use - Screening +"DATA",1130580001.101,16,6,0) +^^2^2^3101013^ +"DATA",1130580001.101,16,6,1,0) +Percentage of patients aged 18 years and older who were screen +"DATA",1130580001.101,16,6,2,0) +ed for unhealthy alcohol use using a systematic method within 24 months +"DATA",1130580001.101,16,7) +^^^^ +"DATA",1130580001.101,23,0) +MU HOS NQF 0495^^ +"DATA",1130580001.101,23,1) +ED THROUGHPUT ARRIVAL TO DEPARTURE +"DATA",1130580001.101,23,5) +ED THROUGHPUT ARRIVAL TO DEPARTURE +"DATA",1130580001.101,23,6,0) +^1130580001.111^3^3^3110430^^^^ +"DATA",1130580001.101,23,6,1,0) +Median time from emergency department arrival to time of departure from +"DATA",1130580001.101,23,6,2,0) +the emergency room for patients admitted to the facility from the +"DATA",1130580001.101,23,6,3,0) +emergency department +"DATA",1130580001.101,23,7) +NQF0495^^^^^^88^165 +"DATA",1130580001.101,24,0) +MU HOS NQF 0497^^ +"DATA",1130580001.101,24,1) +ED THROUGHPUT ADMITTING DECISION TO DEPARTURE +"DATA",1130580001.101,24,5) +ED THROUGHPUT ADMITTING DECISION TO DEPARTURE +"DATA",1130580001.101,24,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,24,6,1,0) +Median time from admit decision time to time of departure from the +"DATA",1130580001.101,24,6,2,0) +emergency department of emergency department patients admitted to +"DATA",1130580001.101,24,6,3,0) +inpatient status +"DATA",1130580001.101,24,7) +NQF0497^^^^^^90^168 +"DATA",1130580001.101,25,0) +MU HOS NQF 0435^^ +"DATA",1130580001.101,25,1) +Ischemic stroke.Discharge on anti-thrombotics +"DATA",1130580001.101,25,5) + Ischemic stroke.Discharge on anti-thrombotic +"DATA",1130580001.101,25,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,25,6,1,0) +Ischemic stroke patients prescribed antithrombotic therapy at hospital +"DATA",1130580001.101,25,6,2,0) +discharge +"DATA",1130580001.101,25,7) +NQF0435^^^^^^114^115 +"DATA",1130580001.101,26,0) +MU HOS NQF 0436^^ +"DATA",1130580001.101,26,1) + Ischemic stroke.Anticoagulation for A-fib/flutter +"DATA",1130580001.101,26,5) +Ischemic stroke.Anticoagulation for A-fib/flutter +"DATA",1130580001.101,26,6,0) +^1130580001.111^2^2^3110430^^^ +"DATA",1130580001.101,26,6,1,0) + Ischemic stroke patients with atrial fibrillation/flutter who are +"DATA",1130580001.101,26,6,2,0) +prescribed anticoagulation therapy at hospital discharge +"DATA",1130580001.101,26,7) +NQF0436^^^^^^116^117 +"DATA",1130580001.101,27,0) +MU HOS NQF 0437^^ +"DATA",1130580001.101,27,1) + Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset +"DATA",1130580001.101,27,5) +Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset +"DATA",1130580001.101,27,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,27,6,1,0) +Acute ischemic stroke patients who arrive at this hospital within 2 +"DATA",1130580001.101,27,6,2,0) +hours of time last known well and for whom IV t-PA was initiated at this +"DATA",1130580001.101,27,6,3,0) +hospital within 3 hours of time last known well. +"DATA",1130580001.101,27,7) +NQF0437^^^^^^119^118 +"DATA",1130580001.101,28,0) +MU HOS NQF 0438^^ +"DATA",1130580001.101,28,1) +Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2 +"DATA",1130580001.101,28,5) +Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2 +"DATA",1130580001.101,28,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,28,6,1,0) +Ischemic stroke patients administered antithrombotic therapy by the +"DATA",1130580001.101,28,6,2,0) +end of hospital day 2. +"DATA",1130580001.101,28,7) +NQF0438^^^^^^120^121 +"DATA",1130580001.101,29,0) +MU HOS NQF 0439^^ +"DATA",1130580001.101,29,1) +Ischemic stroke.Discharge on statins +"DATA",1130580001.101,29,5) +Ischemic stroke.Discharge on statins +"DATA",1130580001.101,29,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,29,6,1,0) +Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or, +"DATA",1130580001.101,29,6,2,0) +who were on a lipid-lowering medication prior to hospital arrival are +"DATA",1130580001.101,29,6,3,0) +prescribed statin medication at hospital discharge +"DATA",1130580001.101,29,7) +NQF0439^^^^^^122^123 +"DATA",1130580001.101,30,0) +MU HOS NQF 0440^^ +"DATA",1130580001.101,30,1) +Ischemic or hemorrhagic stroke.Stroke education +"DATA",1130580001.101,30,5) +Ischemic or hemorrhagic stroke.Stroke education +"DATA",1130580001.101,30,6,0) +^^5^5^3110430^ +"DATA",1130580001.101,30,6,1,0) +Ischemic or hemorrhagic stroke patients or their caregivers who were +"DATA",1130580001.101,30,6,2,0) +given educational materials during the hospital stay addressing all of the +"DATA",1130580001.101,30,6,3,0) +following: activation of emergency medical system, need for follow-up +"DATA",1130580001.101,30,6,4,0) +after discharge, medications prescribed at discharge, risk factors for +"DATA",1130580001.101,30,6,5,0) +stroke, and warning signs and symptoms of stroke. +"DATA",1130580001.101,30,7) +NQF0440^^^^^^124^125 +"DATA",1130580001.101,31,0) +MU HOS NQF 0441^^ +"DATA",1130580001.101,31,1) +Ischemic or hemorrhagic stroke.Rehabilitation assessment +"DATA",1130580001.101,31,5) +Ischemic or hemorrhagic stroke.Rehabilitation assessment +"DATA",1130580001.101,31,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,31,6,1,0) +Ischemic or hemorrhagic stroke patients who were assessed for +"DATA",1130580001.101,31,6,2,0) +rehabilitation services. +"DATA",1130580001.101,31,7) +NQF0441^^^^^^126^127 +"DATA",1130580001.101,32,0) +MU HOS NQF 0371^^ +"DATA",1130580001.101,32,1) +VTE prophylaxis within 24 hours of arrival +"DATA",1130580001.101,32,5) +VTE prophylaxis within 24 hours of arrival +"DATA",1130580001.101,32,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,32,6,1,0) +This measure assesses the number of patients who received VTE prophylaxis +"DATA",1130580001.101,32,6,2,0) +or have documentation why no VTE prophylaxis was given the day of or the +"DATA",1130580001.101,32,6,3,0) +day after hospital admission or surgery end date for surgeries that start +"DATA",1130580001.101,32,6,4,0) +the day of or the day after hospital admission. +"DATA",1130580001.101,32,7) +NQF0371^^^^^^69^67 +"DATA",1130580001.101,33,0) +MU HOS NQF 0372^^ +"DATA",1130580001.101,33,1) +ICU VTE prophylaxis +"DATA",1130580001.101,33,5) +ICU VTE prophylaxis +"DATA",1130580001.101,33,6,0) +^^5^5^3110430^ +"DATA",1130580001.101,33,6,1,0) +This measure assesses the number of patients who received VTE prophylaxis +"DATA",1130580001.101,33,6,2,0) +or have documentation why no VTE prophylaxis was given the day of or the +"DATA",1130580001.101,33,6,3,0) +day after the initial admission (or transfer) to the Intensive Care Unit +"DATA",1130580001.101,33,6,4,0) +(ICU) or surgery end date for surgeries that start the day of or the day +"DATA",1130580001.101,33,6,5,0) +after ICU admission (or transfer). +"DATA",1130580001.101,33,7) +NQF0372^^^^^^128^71 +"DATA",1130580001.101,34,0) +MU HOS NQF 0373^^ +"DATA",1130580001.101,34,1) +Anticoagulation overlap therapy +"DATA",1130580001.101,34,5) +Anticoagulation overlap therapy +"DATA",1130580001.101,34,6,0) +^^8^8^3110430^ +"DATA",1130580001.101,34,6,1,0) +This measure assesses the number of patients diagnosed with confirmed VTE +"DATA",1130580001.101,34,6,2,0) +who received an overlap of parenteral (intravenous [IV] or subcutaneous +"DATA",1130580001.101,34,6,3,0) +[subcu]) anticoagulation and warfarin therapy. For patients who received +"DATA",1130580001.101,34,6,4,0) +less than five days of overlap therapy, they must be discharged on both +"DATA",1130580001.101,34,6,5,0) +medications. Overlap therapy must be administered for at least five days +"DATA",1130580001.101,34,6,6,0) +with an international normalized ratio (INR) . 2 prior to discontinuation +"DATA",1130580001.101,34,6,7,0) +of the parenteral anticoagulation therapy or the patient must be +"DATA",1130580001.101,34,6,8,0) +discharged on both medications. +"DATA",1130580001.101,34,7) +NQF0373^^^^^^129^144 +"DATA",1130580001.101,35,0) +MU HOS NQF 0374^^ +"DATA",1130580001.101,35,1) +Platelet monitoring on unfractionated heparin +"DATA",1130580001.101,35,5) +Platelet monitoring on unfractionated heparin +"DATA",1130580001.101,35,6,0) +^^10^10^3110430^ +"DATA",1130580001.101,35,6,1,0) +This measure assesses the number of patients diagnosed with confirmed VTE +"DATA",1130580001.101,35,6,2,0) +who received intravenous (IV) UFH therapy dosages AND had their platelet +"DATA",1130580001.101,35,6,3,0) +counts monitored using defined parameters such as a nomogram or +"DATA",1130580001.101,35,6,4,0) +protocol This measure assesses the number of patients diagnosed with +"DATA",1130580001.101,35,6,5,0) +confirmed VTE who received intravenous (IV) UFH therapy dosages AND had +"DATA",1130580001.101,35,6,6,0) +their platelet counts monitored using defined parameters such as a +"DATA",1130580001.101,35,6,7,0) +nomogram or protocol This measure assesses the number of patients +"DATA",1130580001.101,35,6,8,0) +diagnosed with confirmed VTE who received intravenous (IV) UFH therapy +"DATA",1130580001.101,35,6,9,0) +dosages AND had their platelet counts monitored using defined parameters +"DATA",1130580001.101,35,6,10,0) +such as a nomogram or protocol +"DATA",1130580001.101,35,7) +NQF0374^^^^^^145^146 +"DATA",1130580001.101,36,0) +MU HOS NQF 0375^^ +"DATA",1130580001.101,36,1) +VTE discharge instructions +"DATA",1130580001.101,36,5) +VTE discharge instructions +"DATA",1130580001.101,36,6,0) +^^11^11^3110430^ +"DATA",1130580001.101,36,6,1,0) +This measure assesses the number of patients diagnosed with confirmed VTE +"DATA",1130580001.101,36,6,2,0) +that are discharged to home, to home with home health, home hospice or +"DATA",1130580001.101,36,6,3,0) +discharged/transferred to court/law enforcement on warfarin with written +"DATA",1130580001.101,36,6,4,0) +discharge instructions that address all four criteria: compliance issues, +"DATA",1130580001.101,36,6,5,0) +dietary advice, follow-up This measure assesses the number of patients +"DATA",1130580001.101,36,6,6,0) +diagnosed with confirmed VTE that are discharged to home, to home with +"DATA",1130580001.101,36,6,7,0) +home health, home hospice or discharged/transferred to court/law +"DATA",1130580001.101,36,6,8,0) +enforcement on warfarin with written discharge instructions that address +"DATA",1130580001.101,36,6,9,0) +all four criteria: compliance issues, dietary advice, follow-up +"DATA",1130580001.101,36,6,10,0) +monitoring, and information about the potential for adverse drug +"DATA",1130580001.101,36,6,11,0) +reactions/interactions. +"DATA",1130580001.101,36,7) +NQF0375^^^^^^147^156 +"DATA",1130580001.101,37,0) +MU HOS NQF 0376^^ +"DATA",1130580001.101,37,1) +Incidence of potentially preventable VTE +"DATA",1130580001.101,37,5) +Incidence of potentially preventable VTE +"DATA",1130580001.101,37,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,37,6,1,0) +This measure assesses the number of patients diagnosed with confirmed VTE +"DATA",1130580001.101,37,6,2,0) +during hospitalization (not present on arrival) who did not receive VTE +"DATA",1130580001.101,37,6,3,0) +prophylaxis between hospital admission and the day before the VTE +"DATA",1130580001.101,37,6,4,0) +diagnostic testing order date. +"DATA",1130580001.101,37,7) +NQF0376^^^^^^158^162 +"DATA",1130580001.101,39,0) +MU EP NQF 0421^^^2.16.840.1.113883.3.249.11.54 +"DATA",1130580001.101,39,1) +NQF0421 Adult Weight Screening and Follow-Up +"DATA",1130580001.101,39,4) +PQRI-128 +"DATA",1130580001.101,39,5) +NQF0421 Adult Weight Screening and Follow-Up +"DATA",1130580001.101,39,6,0) +^1130580001.111^6^6^3110628^^^^ +"DATA",1130580001.101,39,6,1,0) +Percentage of patients aged 18 +"DATA",1130580001.101,39,6,2,0) +years and older with a calculated BMI in the past +"DATA",1130580001.101,39,6,3,0) +six months or during the current visit documented in +"DATA",1130580001.101,39,6,4,0) +the medical record AND if the most recent BMI is +"DATA",1130580001.101,39,6,5,0) +outside parameters, a follow-up plan is +"DATA",1130580001.101,39,6,6,0) +documented. +"DATA",1130580001.101,39,7) +NQF0421^^^^^^321^320^10 +"DATA",1130580001.101,40,0) +MU EP NQF 0013^^^2.16.840.1.113883.3.249.11.56 +"DATA",1130580001.101,40,1) +NQF0013 Hypertension: Blood Pressure Measurement +"DATA",1130580001.101,40,4) +PQRI-13 +"DATA",1130580001.101,40,5) +NQF0013 Hypertension: Blood Pressure Measurement +"DATA",1130580001.101,40,6,0) +^1130580001.111^4^4^3110628^^ +"DATA",1130580001.101,40,6,1,0) +Percentage of patient visits for patients +"DATA",1130580001.101,40,6,2,0) +aged 18 years and older with a diagnosis of hypertension +"DATA",1130580001.101,40,6,3,0) +who have been seen for at least 2 office visits, with blood +"DATA",1130580001.101,40,6,4,0) +pressure (BP) recorded +"DATA",1130580001.101,40,7) +NQF0013^^^^^^142^167 +"DATA",1130580001.101,41,0) +MU EP NQF 0028A^^^2.16.840.1.113883.3.249.11.59 +"DATA",1130580001.101,41,1) +NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention +"DATA",1130580001.101,41,4) +PQRI-28 +"DATA",1130580001.101,41,5) +NQF0028A Tobacco Use Assessment +"DATA",1130580001.101,41,6,0) +^1130580001.111^7^7^3110625^^^ +"DATA",1130580001.101,41,6,1,0) + Percentage of patients aged 18 years and +"DATA",1130580001.101,41,6,2,0) +older who have been seen for at least 2 office visits who +"DATA",1130580001.101,41,6,3,0) +were queried about tobacco use one or more times within +"DATA",1130580001.101,41,6,4,0) +24 months b. Percentage of patients aged 18 years and +"DATA",1130580001.101,41,6,5,0) +older identified as tobacco users within the past 24 +"DATA",1130580001.101,41,6,6,0) +months and have been seen for at least 2 office visits, +"DATA",1130580001.101,41,6,7,0) +who received cessation intervention. +"DATA",1130580001.101,41,7) +NQF0028A^^^^^^157^160 +"DATA",1130580001.101,42,0) +MU EP NQF 0041^^^2.16.840.1.113883.3.249.11.7 +"DATA",1130580001.101,42,1) +Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old +"DATA",1130580001.101,42,4) +PQRI-110 +"DATA",1130580001.101,42,5) +NQF0041 Influenza Immunization 50 years and older +"DATA",1130580001.101,42,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,42,6,1,0) +Percentage of patients aged 50 years +"DATA",1130580001.101,42,6,2,0) +and older who received an influenza immunization +"DATA",1130580001.101,42,6,3,0) +during the flu season (September through +"DATA",1130580001.101,42,6,4,0) +February). +"DATA",1130580001.101,42,7) +NQF0041^^^^^^242^243 +"DATA",1130580001.101,43,0) +MU EP NQF 0024^^ +"DATA",1130580001.101,43,1) +NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL) +"DATA",1130580001.101,43,5) +NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL) +"DATA",1130580001.101,43,6,0) +^^6^6^3120803^ +"DATA",1130580001.101,43,6,1,0) +Percentage of patients 2 -17 years of age +"DATA",1130580001.101,43,6,2,0) +who had an outpatient visit with a Primary Care Physician +"DATA",1130580001.101,43,6,3,0) +(PCP) or OB/GYN and who had evidence of BMI +"DATA",1130580001.101,43,6,4,0) +percentile documentation, counseling for nutrition and +"DATA",1130580001.101,43,6,5,0) +counseling for physical activity during the measurement +"DATA",1130580001.101,43,6,6,0) +year. This specific Quality Measure is for all the children. +"DATA",1130580001.101,43,7) +NQF0024 ALL^^^^^^151^149 +"DATA",1130580001.101,44,0) +MU EP NQF 0038^^^2.16.840.1.113883.3.249.11.60 +"DATA",1130580001.101,44,1) +Childhood Immunization Status +"DATA",1130580001.101,44,4) +PQRI-38 +"DATA",1130580001.101,44,5) +Childhood Immunization Status +"DATA",1130580001.101,44,6,0) +^^14^14^3110430^ +"DATA",1130580001.101,44,6,1,0) +Percentage of children 2 years of age who +"DATA",1130580001.101,44,6,2,0) +had four diphtheria, tetanus and acellular pertussis +"DATA",1130580001.101,44,6,3,0) +(DTaP); three polio(IPV), one measles, ,mumps and +"DATA",1130580001.101,44,6,4,0) +rubella (MMR); two H influenza type B (HiB); three +"DATA",1130580001.101,44,6,5,0) +Percentage of children 2 years of age who +"DATA",1130580001.101,44,6,6,0) +had four diphtheria, tetanus and acellular pertussis +"DATA",1130580001.101,44,6,7,0) +(DTaP); three polio(IPV), one measles, ,mumps and +"DATA",1130580001.101,44,6,8,0) +rubella (MMR); two H influenza type B (HiB); three +"DATA",1130580001.101,44,6,9,0) +hepatitis B (Hep B); one chicken pox (VZV); four +"DATA",1130580001.101,44,6,10,0) +pneumococcal conjugate (PCV); two hepatitis A (Hep A); +"DATA",1130580001.101,44,6,11,0) +two or three rotavirus (RV); and two influenza (flu) +"DATA",1130580001.101,44,6,12,0) +vaccines by their second birthday. The measure +"DATA",1130580001.101,44,6,13,0) +calculates a rate for each vaccine and nine separate +"DATA",1130580001.101,44,6,14,0) +combination rates. +"DATA",1130580001.101,44,7) +NQF0038^^^^ +"DATA",1130580001.101,45,0) +MU EP NQF 0059^^^2.16.840.1.113883.3.249.11.2 +"DATA",1130580001.101,45,1) +Diabetes: Hemoglobin A1c Poor Contro +"DATA",1130580001.101,45,4) +PQRI-1 +"DATA",1130580001.101,45,5) +Diabetes: NQF0059 Hemoglobin A1c Poor Control +"DATA",1130580001.101,45,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,45,6,1,0) +Percentage of patients 18 - 75 years of age with diabetes (type 1 +"DATA",1130580001.101,45,6,2,0) +or type 2) who had hemoglobin A1c > 9.0%. +"DATA",1130580001.101,45,7) +NQF0059^^^^^^260^258 +"DATA",1130580001.101,46,0) +MU EP NQF 0064^^^2.16.840.1.113883.3.249.11.3 +"DATA",1130580001.101,46,1) +Diabetes: Low Density Lipoprotein (LDL) Management and Control +"DATA",1130580001.101,46,4) +PQRI-2 +"DATA",1130580001.101,46,5) +NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control +"DATA",1130580001.101,46,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,46,6,1,0) +Percentage of patients 18-75 years of age with diabetes (type 1 +"DATA",1130580001.101,46,6,2,0) +or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years +"DATA",1130580001.101,46,6,3,0) +of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL). +"DATA",1130580001.101,46,7) +NQF0064^^^^^^248^258 +"DATA",1130580001.101,47,0) +MU EP NQF 0061^^^2.16.840.1.113883.3.249.11.4 +"DATA",1130580001.101,47,1) +Blood Pressure Management +"DATA",1130580001.101,47,4) +PQRI-3 +"DATA",1130580001.101,47,5) +NQF0061 Diabetes: Blood Pressure Management +"DATA",1130580001.101,47,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,47,6,1,0) +Percentage of patients 18 - 75 years of age with +"DATA",1130580001.101,47,6,2,0) +diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg. +"DATA",1130580001.101,47,7) +NQF0061^^^^^^262^258 +"DATA",1130580001.101,48,0) +MU EP NQF 0081^^^2.16.840.1.113883.3.249.11.5 +"DATA",1130580001.101,48,1) +Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) +"DATA",1130580001.101,48,4) +PQRI-5 +"DATA",1130580001.101,48,5) +Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) +"DATA",1130580001.101,48,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,48,6,1,0) +Percentage of patients aged 18 years and older with a +"DATA",1130580001.101,48,6,2,0) +diagnosis of heart failure and LVSD (LVEF < 40%) who were +"DATA",1130580001.101,48,6,3,0) +prescribed ACE inhibitor or ARB therapy +"DATA",1130580001.101,48,7) +NQF0081^^^^ +"DATA",1130580001.101,49,0) +MU EP NQF 0070^^^2.16.840.1.113883.3.249.11.6 +"DATA",1130580001.101,49,1) +CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) +"DATA",1130580001.101,49,4) +PQRI-7 +"DATA",1130580001.101,49,5) +Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy +"DATA",1130580001.101,49,6,0) +^^3^3^3101013^ +"DATA",1130580001.101,49,6,1,0) +Percentage of patients aged 18 years and older with a diagnosis of +"DATA",1130580001.101,49,6,2,0) +coronary artery disease and a prior MI who where prescribed beta-blocker +"DATA",1130580001.101,49,6,3,0) +therapy +"DATA",1130580001.101,49,7) +NQF0070 +"DATA",1130580001.101,50,0) +MU EP NQF 0031^^^2.16.840.1.113883.3.249.11.9 +"DATA",1130580001.101,50,1) +Breast Cancer Screening +"DATA",1130580001.101,50,4) +PQRI-112 +"DATA",1130580001.101,50,5) +Breast Cancer Screening +"DATA",1130580001.101,50,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,50,6,1,0) +Percentage of women 40-69 years of age who had a +"DATA",1130580001.101,50,6,2,0) +mammogram to screen for breast cancer +"DATA",1130580001.101,50,7) +NQF0031^^^^ +"DATA",1130580001.101,51,0) +MU EP NQF 0034^^^2.16.840.1.113883.3.249.11.10 +"DATA",1130580001.101,51,1) +Colorectal Cancer Screening +"DATA",1130580001.101,51,4) +PQRI-113 +"DATA",1130580001.101,51,5) +Colorectal Cancer Screening +"DATA",1130580001.101,51,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,51,6,1,0) +Percentage of adults 50-75 years of age who had appropriate screening for +"DATA",1130580001.101,51,6,2,0) +colorectal cancer. +"DATA",1130580001.101,51,7) +NQF0034^^^^ +"DATA",1130580001.101,52,0) +MU EP NQF 0067^^ +"DATA",1130580001.101,52,1) +Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD +"DATA",1130580001.101,52,5) +Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD +"DATA",1130580001.101,52,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,52,6,1,0) +Percentage of patients aged 18 years and older with a +"DATA",1130580001.101,52,6,2,0) +diagnosis of CAD who were prescribed oral antiplatelet therapy. +"DATA",1130580001.101,52,7) +NQF0067^^^^ +"DATA",1130580001.101,53,0) +MU EP NQF 0083^^ +"DATA",1130580001.101,53,1) +Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) +"DATA",1130580001.101,53,5) +Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) +"DATA",1130580001.101,53,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,53,6,1,0) +Percentage of patients aged 18 years and older with a +"DATA",1130580001.101,53,6,2,0) +diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were +"DATA",1130580001.101,53,6,3,0) +prescribed beta-blocker therapy +"DATA",1130580001.101,53,7) +NQF0083^^^^ +"DATA",1130580001.101,54,0) +MU EP NQF 0105^^ +"DATA",1130580001.101,54,1) +Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment +"DATA",1130580001.101,54,5) +Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment +"DATA",1130580001.101,54,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,54,6,1,0) +The percentage of patients 18 years of age and older +"DATA",1130580001.101,54,6,2,0) +who were diagnosed with a new episode of major depression, treated +"DATA",1130580001.101,54,6,3,0) +with antidepressant medication, and who remained on an +"DATA",1130580001.101,54,6,4,0) +antidepressant medication treatment. +"DATA",1130580001.101,54,7) +NQF0105^^^^ +"DATA",1130580001.101,55,0) +MU EP NQF 0086^^ +"DATA",1130580001.101,55,1) +Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation +"DATA",1130580001.101,55,5) +Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation +"DATA",1130580001.101,55,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,55,6,1,0) +Percentage of patients aged 18 years and older with a +"DATA",1130580001.101,55,6,2,0) +diagnosis of POAG who have been seen for at least two office visits +"DATA",1130580001.101,55,6,3,0) +who have an optic nerve head evaluation during one or more office +"DATA",1130580001.101,55,6,4,0) +visits within 12 months. +"DATA",1130580001.101,55,7) +NQF0086^^^^ +"DATA",1130580001.101,56,0) +MU EP NQF 0088^^ +"DATA",1130580001.101,56,1) +Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy +"DATA",1130580001.101,56,5) +Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy +"DATA",1130580001.101,56,6,0) +^^5^5^3110430^ +"DATA",1130580001.101,56,6,1,0) +Percentage of patients aged 18 years and older with a +"DATA",1130580001.101,56,6,2,0) +diagnosis of diabetic retinopathy who had a dilated macular or fundus +"DATA",1130580001.101,56,6,3,0) +exam performed which included documentation of the level of severity +"DATA",1130580001.101,56,6,4,0) +of retinopathy and the presence or absence of macular edema during +"DATA",1130580001.101,56,6,5,0) +one or more office visits within 12 months. +"DATA",1130580001.101,56,7) +NQF0088^^^^ +"DATA",1130580001.101,57,0) +MU EP NQF 0089^^ +"DATA",1130580001.101,57,1) +Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care +"DATA",1130580001.101,57,5) +Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care +"DATA",1130580001.101,57,6,0) +^^6^6^3110430^ +"DATA",1130580001.101,57,6,1,0) +Percentage of patients aged 18 years and older with a +"DATA",1130580001.101,57,6,2,0) +diagnosis of diabetic retinopathy who had a dilated macular or fundus +"DATA",1130580001.101,57,6,3,0) +exam performed with documented communication to the physician who +"DATA",1130580001.101,57,6,4,0) +manages the ongoing care of the patient with diabetes mellitus +"DATA",1130580001.101,57,6,5,0) +regarding the findings of the macular or fundus exam at least once +"DATA",1130580001.101,57,6,6,0) +within 12 months. +"DATA",1130580001.101,57,7) +NQF0089^^^^ +"DATA",1130580001.101,58,0) +MU EP NQF 0047^^ +"DATA",1130580001.101,58,1) +Asthma Pharmacologic Therapy +"DATA",1130580001.101,58,5) +Asthma Pharmacologic Therapy +"DATA",1130580001.101,58,6,0) +^1130580001.111^4^4^3110430^^ +"DATA",1130580001.101,58,6,1,0) +Percentage of patients aged 5 through 40 years with a +"DATA",1130580001.101,58,6,2,0) +diagnosis of mild, moderate, or severe persistent asthma who were +"DATA",1130580001.101,58,6,3,0) +prescribed either the preferred long-term control medication (inhaled +"DATA",1130580001.101,58,6,4,0) +corticosteroid) or an acceptable alternative treatment +"DATA",1130580001.101,58,7) +NQF0047^^^^ +"DATA",1130580001.101,59,0) +MU EP NQF 0001^^ +"DATA",1130580001.101,59,1) +Asthma Assessment +"DATA",1130580001.101,59,5) +Asthma Assessment +"DATA",1130580001.101,59,6,0) +^^5^5^3110430^ +"DATA",1130580001.101,59,6,1,0) +Percentage of patients aged 5 through 40 years with a +"DATA",1130580001.101,59,6,2,0) +diagnosis of asthma and who have been seen for at least 2 office +"DATA",1130580001.101,59,6,3,0) +visits, who were evaluated during at least one office visit within 12 +"DATA",1130580001.101,59,6,4,0) +months for the frequency (numeric) of daytime and nocturnal asthma +"DATA",1130580001.101,59,6,5,0) +symptoms. +"DATA",1130580001.101,59,7) +NQF0001^^^^ +"DATA",1130580001.101,60,0) +MU EP NQF 0002^^ +"DATA",1130580001.101,60,1) +Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer +"DATA",1130580001.101,60,5) +Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer +"DATA",1130580001.101,60,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,60,6,1,0) +Percentage of female patients aged 18 years and older +"DATA",1130580001.101,60,6,2,0) +with Stage IC through IIIC, ER or PR positive breast cancer who were +"DATA",1130580001.101,60,6,3,0) +prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month +"DATA",1130580001.101,60,6,4,0) +reporting period. +"DATA",1130580001.101,60,7) +NQF0002^^^^ +"DATA",1130580001.101,61,0) +MU EP NQF 0385^^ +"DATA",1130580001.101,61,1) +Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients +"DATA",1130580001.101,61,5) +Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients +"DATA",1130580001.101,61,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,61,6,1,0) +Percentage of patients aged 18 years and older with +"DATA",1130580001.101,61,6,2,0) +Stage IIIA through IIIC colon cancer who are referred for adjuvant +"DATA",1130580001.101,61,6,3,0) +chemotherapy, prescribed adjuvant chemotherapy, or have previously +"DATA",1130580001.101,61,6,4,0) +received adjuvant chemotherapy within the 12-month reporting period +"DATA",1130580001.101,61,7) +NQF0385^^^^ +"DATA",1130580001.101,62,0) +MU EP NQF 0389^^ +"DATA",1130580001.101,62,1) +Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients +"DATA",1130580001.101,62,5) +Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients +"DATA",1130580001.101,62,6,0) +^^5^5^3110430^ +"DATA",1130580001.101,62,6,1,0) +Percentage of patients, regardless of age, with a diagnosis of +"DATA",1130580001.101,62,6,2,0) +prostate cancer at low risk of recurrence receiving interstitial prostate +"DATA",1130580001.101,62,6,3,0) +brachytherapy, OR external beam radiotherapy to the prostate, OR radical +"DATA",1130580001.101,62,6,4,0) +prostatectomy, OR cryotherapy who did not have a bone scan performed at +"DATA",1130580001.101,62,6,5,0) +any time since diagnosis of prostate cancer. +"DATA",1130580001.101,62,7) +NQF0389^^^^ +"DATA",1130580001.101,63,0) +MU EP NQF 0027^^ +"DATA",1130580001.101,63,1) +Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising +"DATA",1130580001.101,63,5) +Smoking and Tobacco Use Cessation +"DATA",1130580001.101,63,6,0) +^^5^5^3110430^ +"DATA",1130580001.101,63,6,1,0) +Percentage of patients 18 years of age and older who were +"DATA",1130580001.101,63,6,2,0) +current smokers or tobacco users, who were seen by a practitioner during +"DATA",1130580001.101,63,6,3,0) +the measurement year and who received advice to quit smoking or tobacco +"DATA",1130580001.101,63,6,4,0) +use or whose practitioner recommended or discussed smoking or tobacco use +"DATA",1130580001.101,63,6,5,0) +cessation medications, methods or strategies +"DATA",1130580001.101,63,7) +NQF0027^^^^ +"DATA",1130580001.101,64,0) +MU EP NQF 0055^^ +"DATA",1130580001.101,64,1) +Diabetes: Eye Exam +"DATA",1130580001.101,64,5) +Diabetes: Eye Exam +"DATA",1130580001.101,64,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,64,6,1,0) +Percentage of patients 18 -75 years of age with diabetes (type 1 +"DATA",1130580001.101,64,6,2,0) +or type 2) who had a retinal or dilated eye exam or a negative retinal +"DATA",1130580001.101,64,6,3,0) +exam (no evidence of retinopathy) by an eye care professional +"DATA",1130580001.101,64,7) +NQF0055^^^^ +"DATA",1130580001.101,65,0) +MU EP NQF 0062^^ +"DATA",1130580001.101,65,1) +Diabetes: Urine Screening +"DATA",1130580001.101,65,5) +Diabetes: Urine Screening +"DATA",1130580001.101,65,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,65,6,1,0) +Percentage of patients 18 - 75 years of age with diabetes (type 1 +"DATA",1130580001.101,65,6,2,0) +or type 2) who had a nephropathy screening test or evidence of +"DATA",1130580001.101,65,6,3,0) +nephropathy. +"DATA",1130580001.101,65,7) +NQF0062^^^^ +"DATA",1130580001.101,66,0) +MU EP NQF 0056^^ +"DATA",1130580001.101,66,1) +Diabetes: Foot Exam +"DATA",1130580001.101,66,5) +Diabetes: Foot Exam +"DATA",1130580001.101,66,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,66,6,1,0) +The percentage of patients aged 18 - 75 years with diabetes +"DATA",1130580001.101,66,6,2,0) +(type 1 or type 2) who had a foot exam (visual inspection, sensory exam +"DATA",1130580001.101,66,6,3,0) +with monofilament, or pulse exam). +"DATA",1130580001.101,66,7) +NQF0056^^^^ +"DATA",1130580001.101,67,0) +MU EP NQF 0074^^ +"DATA",1130580001.101,67,1) +Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol +"DATA",1130580001.101,67,5) +Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol +"DATA",1130580001.101,67,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,67,6,1,0) +Percentage of patients aged 18 years and older with a +"DATA",1130580001.101,67,6,2,0) +diagnosis of CAD who were prescribed a lipid-lowering therapy (based +"DATA",1130580001.101,67,6,3,0) +on current ACC/AHA guidelines). +"DATA",1130580001.101,67,7) +NQF0074^^^^ +"DATA",1130580001.101,68,0) +MU EP NQF 0084^^ +"DATA",1130580001.101,68,1) +Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation +"DATA",1130580001.101,68,5) +Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation +"DATA",1130580001.101,68,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,68,6,1,0) +Percentage of all patients aged 18 years and older with a +"DATA",1130580001.101,68,6,2,0) +diagnosis of heart failure and paroxysmal or chronic atrial fibrillation +"DATA",1130580001.101,68,6,3,0) +who were prescribed warfarin therapy. +"DATA",1130580001.101,68,7) +NQF0084^^^^ +"DATA",1130580001.101,69,0) +MU EP NQF 0073^^ +"DATA",1130580001.101,69,1) +Ischemic Vascular Disease (IVD): Blood Pressure Management +"DATA",1130580001.101,69,5) +Ischemic Vascular Disease (IVD): Blood Pressure Management +"DATA",1130580001.101,69,6,0) +^^11^11^3110430^ +"DATA",1130580001.101,69,6,1,0) +Percentage of patients 18 years of age and older who +"DATA",1130580001.101,69,6,2,0) +were discharged alive for acute myocardial infarction (AMI), coronary +"DATA",1130580001.101,69,6,3,0) +artery bypass graft (CABG) or percutaneous transluminal coronary +"DATA",1130580001.101,69,6,4,0) +Percentage of patients 18 years of age and older who +"DATA",1130580001.101,69,6,5,0) +were discharged alive for acute myocardial infarction (AMI), coronary +"DATA",1130580001.101,69,6,6,0) +artery bypass graft (CABG) or percutaneous transluminal coronary +"DATA",1130580001.101,69,6,7,0) +angioplasty (PTCA) from January 1- November 1 of the year prior to +"DATA",1130580001.101,69,6,8,0) +the measurement year, or who had a diagnosis of ischemic vascular +"DATA",1130580001.101,69,6,9,0) +disease (IVD) during the measurement year and the year prior to the +"DATA",1130580001.101,69,6,10,0) +measurement year and whose recent blood pressure is in control +"DATA",1130580001.101,69,6,11,0) +(<140/90 mmHg). +"DATA",1130580001.101,69,7) +NQF0073^^^^ +"DATA",1130580001.101,70,0) +MU EP NQF 0068^^ +"DATA",1130580001.101,70,1) +Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic +"DATA",1130580001.101,70,5) + Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic +"DATA",1130580001.101,70,6,0) +^^8^8^3110430^ +"DATA",1130580001.101,70,6,1,0) + Percentage of patients 18 years of age and older who were +"DATA",1130580001.101,70,6,2,0) +discharged alive for acute myocardial infarction (AMI), coronary artery +"DATA",1130580001.101,70,6,3,0) +bypass graft (CABG) or percutaneous transluminal coronary +"DATA",1130580001.101,70,6,4,0) +angioplasty (PTCA) from January 1-November 1 of the year prior to the +"DATA",1130580001.101,70,6,5,0) +measurement year, or who had a diagnosis of ischemic vascular +"DATA",1130580001.101,70,6,6,0) +disease (IVD) during the measurement year and the year prior to the +"DATA",1130580001.101,70,6,7,0) +measurement year and who had documentation of use of aspirin or +"DATA",1130580001.101,70,6,8,0) +another antithrombotic during the measurement year +"DATA",1130580001.101,70,7) +NQF0068^^^^ +"DATA",1130580001.101,71,0) +MU EP NQF 0004^^ +"DATA",1130580001.101,71,1) + Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement +"DATA",1130580001.101,71,5) +Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a) Initiation,(b) Engagement +"DATA",1130580001.101,71,6,0) +^^6^6^3110430^ +"DATA",1130580001.101,71,6,1,0) +The percentage of adolescent and adult patients with a new +"DATA",1130580001.101,71,6,2,0) +episode of alcohol and other drug (AOD) dependence who initiate treatment +"DATA",1130580001.101,71,6,3,0) +through an inpatient AOD admission, outpatient visit, intensive +"DATA",1130580001.101,71,6,4,0) +outpatient encounter or partial hospitalization within 14 days of the +"DATA",1130580001.101,71,6,5,0) +diagnosis and who initiated treatment and who had two or more additional +"DATA",1130580001.101,71,6,6,0) +services with an AOD diagnosis within 30 days of the initiation visit. +"DATA",1130580001.101,71,7) +NQF0004^^^^ +"DATA",1130580001.101,72,0) +MU EP NQF 0012^^ +"DATA",1130580001.101,72,1) +Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) +"DATA",1130580001.101,72,5) +Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) +"DATA",1130580001.101,72,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,72,6,1,0) +Percentage of patients, regardless of age, who gave birth during +"DATA",1130580001.101,72,6,2,0) +a 12-month period who were screened for HIV infection during the first or +"DATA",1130580001.101,72,6,3,0) +second prenatal care visit. +"DATA",1130580001.101,72,7) +NQF0012^^^^ +"DATA",1130580001.101,73,0) +MU EP NQF 0014^^ +"DATA",1130580001.101,73,1) +Prenatal Care: Anti-D Immune Globulin +"DATA",1130580001.101,73,5) +Prenatal Care: Anti-D Immune Globulin +"DATA",1130580001.101,73,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,73,6,1,0) +Percentage of D (Rh) negative, unsensitized patients, regardless +"DATA",1130580001.101,73,6,2,0) +of age, who gave birth during a 12-month period who received anti-D +"DATA",1130580001.101,73,6,3,0) +immune globulin at 26-30 weeks gestation. +"DATA",1130580001.101,73,7) +NQD0014^^^^ +"DATA",1130580001.101,74,0) +MU EP NQF 0018^^ +"DATA",1130580001.101,74,1) +Controlling High Blood Pressure +"DATA",1130580001.101,74,5) +Controlling High Blood Pressure +"DATA",1130580001.101,74,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,74,6,1,0) +The percentage of patients 18-85 years of age who had a +"DATA",1130580001.101,74,6,2,0) +diagnosis of hypertension and whose BP was adequately controlled during +"DATA",1130580001.101,74,6,3,0) +the measurement year +"DATA",1130580001.101,74,7) +NQF0018^^^^ +"DATA",1130580001.101,75,0) +MU EP NQF 0032^^ +"DATA",1130580001.101,75,1) +Cervical Cancer Screening +"DATA",1130580001.101,75,5) +Cervical Cancer Screening +"DATA",1130580001.101,75,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,75,6,1,0) +Percentage of women 21-64 years of age, who received one or +"DATA",1130580001.101,75,6,2,0) +more Pap tests to screen for cervical cancer +"DATA",1130580001.101,75,7) +NQF0032^^^^ +"DATA",1130580001.101,76,0) +MU EP NQF 0033^^ +"DATA",1130580001.101,76,1) +Chlamydia Screening for Women +"DATA",1130580001.101,76,5) +Chlamydia Screening for Women +"DATA",1130580001.101,76,6,0) +^^3^3^3110430^ +"DATA",1130580001.101,76,6,1,0) +Percentage of women 15- 24 years of age who were identified as sexually +"DATA",1130580001.101,76,6,2,0) +active and who had at least one test for chlamydia during the measurement +"DATA",1130580001.101,76,6,3,0) +year. +"DATA",1130580001.101,76,7) +NQF0033^^^^ +"DATA",1130580001.101,77,0) +MU EP NQF 0036^^ +"DATA",1130580001.101,77,1) +Use of Appropriate Medications for Asthma +"DATA",1130580001.101,77,5) +Use of Appropriate Medications for Asthma +"DATA",1130580001.101,77,6,0) +^^4^4^3110430^ +"DATA",1130580001.101,77,6,1,0) +Percentage of patients 5 - 50 years of age who were identified as having +"DATA",1130580001.101,77,6,2,0) +persistent asthma and were appropriately prescribed medication during the +"DATA",1130580001.101,77,6,3,0) +measurement year. Report three age stratifications (5-11 years, 12-50 +"DATA",1130580001.101,77,6,4,0) +years, and total). +"DATA",1130580001.101,77,7) +NQF0036^^^^ +"DATA",1130580001.101,78,0) +MU EP NQF 0052^^ +"DATA",1130580001.101,78,1) +Low Back Pain: Use of Imaging Studies +"DATA",1130580001.101,78,5) +Low Back Pain: Use of Imaging Studies +"DATA",1130580001.101,78,6,0) +^1130580001.111^3^3^3110430^^ +"DATA",1130580001.101,78,6,1,0) +Percentage of patients with a primary diagnosis of low back pain +"DATA",1130580001.101,78,6,2,0) +who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 +"DATA",1130580001.101,78,6,3,0) +days of diagnosis. +"DATA",1130580001.101,78,7) +NQF0052^^^^ +"DATA",1130580001.101,79,0) +MU EP NQF 0075^^ +"DATA",1130580001.101,79,1) +Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control +"DATA",1130580001.101,79,5) +Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control +"DATA",1130580001.101,79,6,0) +^^7^7^3110430^ +"DATA",1130580001.101,79,6,1,0) +Percentage of patients 18 years of age and older who were discharged alive +"DATA",1130580001.101,79,6,2,0) +for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) +"DATA",1130580001.101,79,6,3,0) +or percutaneous transluminal angioplasty (PTCA) from January 1-November1 +"DATA",1130580001.101,79,6,4,0) +of the year prior to the measurement year, or who had a diagnosis of +"DATA",1130580001.101,79,6,5,0) +ischemic vascular disease (IVD) during the measurement year and the year +"DATA",1130580001.101,79,6,6,0) +prior to the measurement year and who had a complete lipid profile +"DATA",1130580001.101,79,6,7,0) +performed during the measurement year and whose LDL-C<100 mg/dL +"DATA",1130580001.101,79,7) +NQF0075^^^^ +"DATA",1130580001.101,80,0) +MU EP NQF 0575^^ +"DATA",1130580001.101,80,1) +Diabetes: Hemoglobin A1c Control (<8.0%) +"DATA",1130580001.101,80,5) +Diabetes: Hemoglobin A1c Control (<8.0%) +"DATA",1130580001.101,80,6,0) +^^2^2^3110430^ +"DATA",1130580001.101,80,6,1,0) +The percentage of patients 18-75 years of age with diabetes +"DATA",1130580001.101,80,6,2,0) +(type 1 or type 2) who had hemoglobin A1c <8.0% +"DATA",1130580001.101,80,7) +NQF0575^^^^ +"DATA",1130580001.101,81,0) +MU EP NQF 0028B^^ +"DATA",1130580001.101,81,1) +NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention +"DATA",1130580001.101,81,5) +NQF0028B Tobacco Use Assessment and Cessation Intervention +"DATA",1130580001.101,81,6,0) +^1130580001.111^7^7^3110625^^^^ +"DATA",1130580001.101,81,6,1,0) + Percentage of patients aged 18 years and +"DATA",1130580001.101,81,6,2,0) +older who have been seen for at least 2 office visits who +"DATA",1130580001.101,81,6,3,0) +were queried about tobacco use one or more times within +"DATA",1130580001.101,81,6,4,0) +24 months b. Percentage of patients aged 18 years and +"DATA",1130580001.101,81,6,5,0) +older identified as tobacco users within the past 24 +"DATA",1130580001.101,81,6,6,0) +months and have been seen for at least 2 office visits, +"DATA",1130580001.101,81,6,7,0) +who received cessation intervention. +"DATA",1130580001.101,81,7) +NQF0028B^^^^^^154^160 +"DATA",1130580001.101,82,0) +MU EP NQF 0024 2-10Y +"DATA",1130580001.101,82,1) +NQF0024 Weight Assessment and Counseling for Children and Adolescents (2-10) +"DATA",1130580001.101,82,5) +Weight Assessment and Counseling for Children 2-10 Years Old +"DATA",1130580001.101,82,6,0) +^^6^6^3120803^ +"DATA",1130580001.101,82,6,1,0) +Percentage of patients 2-10 years of age +"DATA",1130580001.101,82,6,2,0) +who had an outpatient visit with a Primary Care Physician +"DATA",1130580001.101,82,6,3,0) +(PCP) or OB/GYN and who had evidence of BMI +"DATA",1130580001.101,82,6,4,0) +percentile documentation, counseling for nutrition and +"DATA",1130580001.101,82,6,5,0) +counseling for physical activity during the measurement +"DATA",1130580001.101,82,6,6,0) +year. Only for those 2-10 years of age. +"DATA",1130580001.101,82,7) +NQF0024 2-10Y^^^^^^334^338 +"DATA",1130580001.101,83,0) +MU EP NQF 0038 NUM1 DPT^^ +"DATA",1130580001.101,83,5) +NQF0038 NUM1 DPT +"DATA",1130580001.101,83,7) +NQF0038 NUM1 DPT^^^^^^329^192^11 +"DATA",1130580001.101,84,0) +MU EP NQF 0038 NUM2 IPV^^ +"DATA",1130580001.101,84,5) +NQF0038 NUM2 IPV +"DATA",1130580001.101,84,7) +NQF0038 NUM2 IPV^^^^^^224^192^11 +"DATA",1130580001.101,85,0) +MU EP NQF 0038 NUM3 MMR^^ +"DATA",1130580001.101,85,5) +NQF0038 NUM3 MMR +"DATA",1130580001.101,85,7) +NQF0038 NUM3 MMR^^^^^^183^192^11 +"DATA",1130580001.101,86,0) +MU EP NQF 0038 NUM4 HiB^^ +"DATA",1130580001.101,86,5) +NQF0038 NUM4 HiB +"DATA",1130580001.101,86,7) +NQF0038 NUM4 HiB^^^^^^189^192^11 +"DATA",1130580001.101,87,0) +MU EP NQF 0038 NUM5 HEP B^^ +"DATA",1130580001.101,87,5) +NQF0038 NUM5 HEP B +"DATA",1130580001.101,87,7) +NQF0038 NUM5 HEP B^^^^^^194^192^11 +"DATA",1130580001.101,88,0) +MU EP NQF 0038 NUM6 VZV^^ +"DATA",1130580001.101,88,5) +NQF0038 NUM6 VZV +"DATA",1130580001.101,88,7) +NQF0038 NUM6 VZV^^^^^^198^192^11 +"DATA",1130580001.101,89,0) +MU EP NQF 0038 NUM7 PCV^^ +"DATA",1130580001.101,89,5) +NQF0038 NUM7 PCV +"DATA",1130580001.101,89,7) +NQF0038 NUM7 PCV^^^^^^205^192^11 +"DATA",1130580001.101,90,0) +MU EP NQF 0038 NUM8 HEP A^^ +"DATA",1130580001.101,90,5) +NQF0038 NUM8 HEP A +"DATA",1130580001.101,90,7) +NQF0038 NUM8 HEP A^^^^^^208^192^11 +"DATA",1130580001.101,91,0) +MU EP NQF 0038 NUM9 RV^^ +"DATA",1130580001.101,91,5) +NQF0038 NUM9 +"DATA",1130580001.101,91,7) +NQF0038 NUM9^^^^^^216^192^11 +"DATA",1130580001.101,92,0) +MU EP NQF 0038 NUM10 FLU^^ +"DATA",1130580001.101,92,5) +NQF0038 NUM10 +"DATA",1130580001.101,92,7) +NQF0038 NUM10^^^^^^331^192^11 +"DATA",1130580001.101,93,0) +MU EP NQF 0038 NUM11 COMBO5^^ +"DATA",1130580001.101,93,5) +NQF0038 NUM11 COMBO5 +"DATA",1130580001.101,93,7) +NQF0038 NUM11 COMBO5^^^^^^228^192^11 +"DATA",1130580001.101,94,0) +MU EP NQF 0038 NUM12 COMBO6^^ +"DATA",1130580001.101,94,5) +NQF0038 NUM12 COMBO6 +"DATA",1130580001.101,94,7) +NQF0038 NUM12 COMBO6^^^^^^231^192^11 +"DATA",1130580001.101,95,0) +MU 2011 INP ADV DIRECTIVES^^ +"DATA",1130580001.101,95,5) +Advance Directives +"DATA",1130580001.101,95,7) +^^^^ +"DATA",1130580001.101,96,0) +MU 2011 INP CPOE^^ +"DATA",1130580001.101,96,5) +CPOE for Medications +"DATA",1130580001.101,96,7) +^^^^ +"DATA",1130580001.101,97,0) +MU 2011 INP MED RECON^^ +"DATA",1130580001.101,97,5) +Medication Reconcilliation +"DATA",1130580001.101,97,7) +^^^^ +"DATA",1130580001.101,98,0) +MU 2011 INP PROBLEM LIST^^ +"DATA",1130580001.101,98,5) +Problem List +"DATA",1130580001.101,98,7) +^^^^ +"DATA",1130580001.101,99,0) +MU 2011 INP VITAL SIGNS^^ +"DATA",1130580001.101,99,5) +Record Vital Signs +"DATA",1130580001.101,99,7) +^^^^ +"DATA",1130580001.101,100,0) +MU 2011 INP SMOKING STATUS^^ +"DATA",1130580001.101,100,5) +Smoking Status +"DATA",1130580001.101,100,7) +^^^^ +"DATA",1130580001.101,101,0) +MU 2011 INP MED LIST^^ +"DATA",1130580001.101,101,5) +Active Medication List +"DATA",1130580001.101,101,7) +^^^^ +"DATA",1130580001.101,102,0) +MU 2011 INP ALLERGY LIST^^ +"DATA",1130580001.101,102,5) +Medication Allergy List +"DATA",1130580001.101,102,7) +^^^^ +"DATA",1130580001.101,103,0) +MU 2011 INP DEMOGRAPHICS^^ +"DATA",1130580001.101,103,5) +Record Demographics +"DATA",1130580001.101,103,7) +^^^^ +"DATA",1130580001.101,104,0) +MU EP NQF 0024 11-17Y +"DATA",1130580001.101,104,1) +NQF0024 Weight Assessment and Counseling for Children and Adolescents (11-17) +"DATA",1130580001.101,104,5) +Weight Assessment and Counseling for Children and Adolescents 11-17 years old +"DATA",1130580001.101,104,6,0) +^^6^6^3120803^ +"DATA",1130580001.101,104,6,1,0) +Percentage of patients 11-17 years of age +"DATA",1130580001.101,104,6,2,0) +who had an outpatient visit with a Primary Care Physician +"DATA",1130580001.101,104,6,3,0) +(PCP) or OB/GYN and who had evidence of BMI +"DATA",1130580001.101,104,6,4,0) +percentile documentation, counseling for nutrition and +"DATA",1130580001.101,104,6,5,0) +counseling for physical activity during the measurement +"DATA",1130580001.101,104,6,6,0) +year. Only for those 11-17 years old. +"DATA",1130580001.101,104,7) +NQF0024 11-17Y^^^^^^336^340 +"FIA",1130580001.101) +C0Q QUALITY MEASURE +"FIA",1130580001.101,0) +^C0Q(101, +"FIA",1130580001.101,0,0) +1130580001.101I +"FIA",1130580001.101,0,1) +y^y^f^^y^^y^o^n +"FIA",1130580001.101,0,10) + +"FIA",1130580001.101,0,11) + +"FIA",1130580001.101,0,"RLRO") + +"FIA",1130580001.101,0,"VR") +1.0^C0Q +"FIA",1130580001.101,1130580001.101) +0 +"FIA",1130580001.101,1130580001.111) +0 +"FRV1",1130580001.101,"104,7",7) +MU NQF0024 BMI PERCENTILE 11-17Y RS +"FRV1",1130580001.101,"104,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"104,7",8) +MU NQF0024 BMI 11-17Y DENOM RS +"FRV1",1130580001.101,"104,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"23,7",7) +MU ED-1 NUMER RS +"FRV1",1130580001.101,"23,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"23,7",8) +MU ED-1 DENOM RS +"FRV1",1130580001.101,"23,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"24,7",7) +MU ED-2 NUMER RS +"FRV1",1130580001.101,"24,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"24,7",8) +MU ED-2 DENOM RS +"FRV1",1130580001.101,"24,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"25,7",7) +MU STK-2 NUMER RS +"FRV1",1130580001.101,"25,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"25,7",8) +MU STK-2 DENOM RS +"FRV1",1130580001.101,"25,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"26,7",7) +MU STK-3 NUMER RS +"FRV1",1130580001.101,"26,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"26,7",8) +MU STK-3 DENOM RS +"FRV1",1130580001.101,"26,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"27,7",7) +MU STK-4 NUMER RS +"FRV1",1130580001.101,"27,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"27,7",8) +MU STK-4 DENOM RS +"FRV1",1130580001.101,"27,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"28,7",7) +MU STK-5 NUMER RS +"FRV1",1130580001.101,"28,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"28,7",8) +MU STK-5 DENOM RS +"FRV1",1130580001.101,"28,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"29,7",7) +MU STK-6 NUMER RS +"FRV1",1130580001.101,"29,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"29,7",8) +MU STK-6 DENOM RS +"FRV1",1130580001.101,"29,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"30,7",7) +MU STK-8 NUMER RS +"FRV1",1130580001.101,"30,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"30,7",8) +MU STK-8 DENOM RS +"FRV1",1130580001.101,"30,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"31,7",7) +MU STK-10 NUMER RS +"FRV1",1130580001.101,"31,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"31,7",8) +MU STK-10 DENOM RS +"FRV1",1130580001.101,"31,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"32,7",7) +MU VTE-1 NUMER RS +"FRV1",1130580001.101,"32,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"32,7",8) +MU VTE-1 DENOM RS +"FRV1",1130580001.101,"32,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"33,7",7) +MU VTE-2 NUMER RS +"FRV1",1130580001.101,"33,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"33,7",8) +MU VTE-2 DENOM RS +"FRV1",1130580001.101,"33,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"34,7",7) +MU VTE-3 NUMER RS +"FRV1",1130580001.101,"34,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"34,7",8) +MU VTE-3 DENOM RS +"FRV1",1130580001.101,"34,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"35,7",7) +MU VTE-4 NUMER RS +"FRV1",1130580001.101,"35,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"35,7",8) +MU VTE-4 DENOM RS +"FRV1",1130580001.101,"35,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"36,7",7) +MU VTE-5 NUMER RS +"FRV1",1130580001.101,"36,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"36,7",8) +MU VTE-5 DENOM RS +"FRV1",1130580001.101,"36,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"37,7",7) +MU VTE-6 NUMER RS +"FRV1",1130580001.101,"37,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"37,7",8) +MU VTE-6 DENOM RS +"FRV1",1130580001.101,"37,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"39,7",7) +MU NQF0421 BMI NUM ALL RS +"FRV1",1130580001.101,"39,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"39,7",8) +MU NQF0421 BMI DENOM ALL RS +"FRV1",1130580001.101,"39,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"39,7",9) +MU NQF0421 ADULT BMI +"FRV1",1130580001.101,"39,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"40,7",7) +MU NQF0013 HTN NUMER2 RS +"FRV1",1130580001.101,"40,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"40,7",8) +MU NQF0013 HTN DENOM2 RS +"FRV1",1130580001.101,"40,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"41,7",7) +MU NQF0028A TOBACCO SCREEN NUM RS +"FRV1",1130580001.101,"41,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"41,7",8) +MU NQF0028B TOBACCO INTERV DENOM RS +"FRV1",1130580001.101,"41,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"42,7",7) +MU NQF0041 FLU RS +"FRV1",1130580001.101,"42,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"42,7",8) +MU NQF0041 FLU DENOM RS +"FRV1",1130580001.101,"42,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"43,7",7) +MU NQF0024 BMI 2-17YR NUM RS +"FRV1",1130580001.101,"43,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"43,7",8) +MU NQF0024 BMI 2-17YRS DEM RS +"FRV1",1130580001.101,"43,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"45,7",7) +MU NQF0059 HBA1C NUM RS +"FRV1",1130580001.101,"45,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"45,7",8) +MU NQF0059 DM DENOM-ALL RS +"FRV1",1130580001.101,"45,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"46,7",7) +MU NQF0064 NUM LDL RS +"FRV1",1130580001.101,"46,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"46,7",8) +MU NQF0059 DM DENOM-ALL RS +"FRV1",1130580001.101,"46,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"47,7",7) +MU NQF0061 NUM DM BP<140/90 RS +"FRV1",1130580001.101,"47,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"47,7",8) +MU NQF0059 DM DENOM-ALL RS +"FRV1",1130580001.101,"47,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"81,7",7) +MU NQF0028B TOBACCO INTERV NUM2 RS +"FRV1",1130580001.101,"81,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"81,7",8) +MU NQF0028B TOBACCO INTERV DENOM RS +"FRV1",1130580001.101,"81,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"82,7",7) +MU NQF0024 BMI PERCENTILE 2-10Y RS +"FRV1",1130580001.101,"82,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"82,7",8) +MU NQF0024 BMI 2-10Y DENOM RS +"FRV1",1130580001.101,"82,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"83,7",7) +MU NQF0038 NUM1 DPT RS +"FRV1",1130580001.101,"83,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"83,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"83,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"83,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"83,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"84,7",7) +MU NQF0038 NUM2 IPV RS +"FRV1",1130580001.101,"84,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"84,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"84,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"84,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"84,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"85,7",7) +MU NQF0038 NUM3-ALL RS +"FRV1",1130580001.101,"85,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"85,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"85,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"85,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"85,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"86,7",7) +MU NQF0038 NUM4 HIB RS +"FRV1",1130580001.101,"86,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"86,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"86,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"86,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"86,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"87,7",7) +MU NQF0038 NUM5 RS +"FRV1",1130580001.101,"87,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"87,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"87,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"87,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"87,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"88,7",7) +MU NQF0038 NUM6 VZV RS +"FRV1",1130580001.101,"88,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"88,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"88,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"88,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"88,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"89,7",7) +MU NQF0038 NUM7 PCV RS +"FRV1",1130580001.101,"89,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"89,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"89,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"89,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"89,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"90,7",7) +MU NQF0038 NUM8 HEP A RS +"FRV1",1130580001.101,"90,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"90,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"90,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"90,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"90,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"91,7",7) +MU NQF0038 NUM9 RV RS +"FRV1",1130580001.101,"91,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"91,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"91,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"91,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"91,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"92,7",7) +MU NQF0038 NUM10 INFLUENZA RS +"FRV1",1130580001.101,"92,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"92,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"92,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"92,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"92,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"93,7",7) +MU NQF0038 NUM11 COMBO5 RS +"FRV1",1130580001.101,"93,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"93,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"93,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"93,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"93,7",9,"F") +;PXRM(810.2, +"FRV1",1130580001.101,"94,7",7) +MU NQF0038 NUM12 COMBO6 RS +"FRV1",1130580001.101,"94,7",7,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"94,7",8) +MU NQF0038 DENOM RS +"FRV1",1130580001.101,"94,7",8,"F") +;PXRM(810.4, +"FRV1",1130580001.101,"94,7",9) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1",1130580001.101,"94,7",9,"F") +;PXRM(810.2, +"FRV1K",1130580001.101,"104,7",7) +B +"FRV1K",1130580001.101,"104,7",7,1) +MU NQF0024 BMI PERCENTILE 11-17Y RS +"FRV1K",1130580001.101,"104,7",8) +B +"FRV1K",1130580001.101,"104,7",8,1) +MU NQF0024 BMI 11-17Y DENOM RS +"FRV1K",1130580001.101,"23,7",7) +B +"FRV1K",1130580001.101,"23,7",7,1) +MU ED-1 NUMER RS +"FRV1K",1130580001.101,"23,7",8) +B +"FRV1K",1130580001.101,"23,7",8,1) +MU ED-1 DENOM RS +"FRV1K",1130580001.101,"24,7",7) +B +"FRV1K",1130580001.101,"24,7",7,1) +MU ED-2 NUMER RS +"FRV1K",1130580001.101,"24,7",8) +B +"FRV1K",1130580001.101,"24,7",8,1) +MU ED-2 DENOM RS +"FRV1K",1130580001.101,"25,7",7) +B +"FRV1K",1130580001.101,"25,7",7,1) +MU STK-2 NUMER RS +"FRV1K",1130580001.101,"25,7",8) +B +"FRV1K",1130580001.101,"25,7",8,1) +MU STK-2 DENOM RS +"FRV1K",1130580001.101,"26,7",7) +B +"FRV1K",1130580001.101,"26,7",7,1) +MU STK-3 NUMER RS +"FRV1K",1130580001.101,"26,7",8) +B +"FRV1K",1130580001.101,"26,7",8,1) +MU STK-3 DENOM RS +"FRV1K",1130580001.101,"27,7",7) +B +"FRV1K",1130580001.101,"27,7",7,1) +MU STK-4 NUMER RS +"FRV1K",1130580001.101,"27,7",8) +B +"FRV1K",1130580001.101,"27,7",8,1) +MU STK-4 DENOM RS +"FRV1K",1130580001.101,"28,7",7) +B +"FRV1K",1130580001.101,"28,7",7,1) +MU STK-5 NUMER RS +"FRV1K",1130580001.101,"28,7",8) +B +"FRV1K",1130580001.101,"28,7",8,1) +MU STK-5 DENOM RS +"FRV1K",1130580001.101,"29,7",7) +B +"FRV1K",1130580001.101,"29,7",7,1) +MU STK-6 NUMER RS +"FRV1K",1130580001.101,"29,7",8) +B +"FRV1K",1130580001.101,"29,7",8,1) +MU STK-6 DENOM RS +"FRV1K",1130580001.101,"30,7",7) +B +"FRV1K",1130580001.101,"30,7",7,1) +MU STK-8 NUMER RS +"FRV1K",1130580001.101,"30,7",8) +B +"FRV1K",1130580001.101,"30,7",8,1) +MU STK-8 DENOM RS +"FRV1K",1130580001.101,"31,7",7) +B +"FRV1K",1130580001.101,"31,7",7,1) +MU STK-10 NUMER RS +"FRV1K",1130580001.101,"31,7",8) +B +"FRV1K",1130580001.101,"31,7",8,1) +MU STK-10 DENOM RS +"FRV1K",1130580001.101,"32,7",7) +B +"FRV1K",1130580001.101,"32,7",7,1) +MU VTE-1 NUMER RS +"FRV1K",1130580001.101,"32,7",8) +B +"FRV1K",1130580001.101,"32,7",8,1) +MU VTE-1 DENOM RS +"FRV1K",1130580001.101,"33,7",7) +B +"FRV1K",1130580001.101,"33,7",7,1) +MU VTE-2 NUMER RS +"FRV1K",1130580001.101,"33,7",8) +B +"FRV1K",1130580001.101,"33,7",8,1) +MU VTE-2 DENOM RS +"FRV1K",1130580001.101,"34,7",7) +B +"FRV1K",1130580001.101,"34,7",7,1) +MU VTE-3 NUMER RS +"FRV1K",1130580001.101,"34,7",8) +B +"FRV1K",1130580001.101,"34,7",8,1) +MU VTE-3 DENOM RS +"FRV1K",1130580001.101,"35,7",7) +B +"FRV1K",1130580001.101,"35,7",7,1) +MU VTE-4 NUMER RS +"FRV1K",1130580001.101,"35,7",8) +B +"FRV1K",1130580001.101,"35,7",8,1) +MU VTE-4 DENOM RS +"FRV1K",1130580001.101,"36,7",7) +B +"FRV1K",1130580001.101,"36,7",7,1) +MU VTE-5 NUMER RS +"FRV1K",1130580001.101,"36,7",8) +B +"FRV1K",1130580001.101,"36,7",8,1) +MU VTE-5 DENOM RS +"FRV1K",1130580001.101,"37,7",7) +B +"FRV1K",1130580001.101,"37,7",7,1) +MU VTE-6 NUMER RS +"FRV1K",1130580001.101,"37,7",8) +B +"FRV1K",1130580001.101,"37,7",8,1) +MU VTE-6 DENOM RS +"FRV1K",1130580001.101,"39,7",7) +B +"FRV1K",1130580001.101,"39,7",7,1) +MU NQF0421 BMI NUM ALL RS +"FRV1K",1130580001.101,"39,7",8) +B +"FRV1K",1130580001.101,"39,7",8,1) +MU NQF0421 BMI DENOM ALL RS +"FRV1K",1130580001.101,"39,7",9) +B +"FRV1K",1130580001.101,"39,7",9,1) +MU NQF0421 ADULT BMI +"FRV1K",1130580001.101,"40,7",7) +B +"FRV1K",1130580001.101,"40,7",7,1) +MU NQF0013 HTN NUMER2 RS +"FRV1K",1130580001.101,"40,7",8) +B +"FRV1K",1130580001.101,"40,7",8,1) +MU NQF0013 HTN DENOM2 RS +"FRV1K",1130580001.101,"41,7",7) +B +"FRV1K",1130580001.101,"41,7",7,1) +MU NQF0028A TOBACCO SCREEN NUM RS +"FRV1K",1130580001.101,"41,7",8) +B +"FRV1K",1130580001.101,"41,7",8,1) +MU NQF0028B TOBACCO INTERV DENOM RS +"FRV1K",1130580001.101,"42,7",7) +B +"FRV1K",1130580001.101,"42,7",7,1) +MU NQF0041 FLU RS +"FRV1K",1130580001.101,"42,7",8) +B +"FRV1K",1130580001.101,"42,7",8,1) +MU NQF0041 FLU DENOM RS +"FRV1K",1130580001.101,"43,7",7) +B +"FRV1K",1130580001.101,"43,7",7,1) +MU NQF0024 BMI 2-17YR NUM RS +"FRV1K",1130580001.101,"43,7",8) +B +"FRV1K",1130580001.101,"43,7",8,1) +MU NQF0024 BMI 2-17YRS DEM RS +"FRV1K",1130580001.101,"45,7",7) +B +"FRV1K",1130580001.101,"45,7",7,1) +MU NQF0059 HBA1C NUM RS +"FRV1K",1130580001.101,"45,7",8) +B +"FRV1K",1130580001.101,"45,7",8,1) +MU NQF0059 DM DENOM-ALL RS +"FRV1K",1130580001.101,"46,7",7) +B +"FRV1K",1130580001.101,"46,7",7,1) +MU NQF0064 NUM LDL RS +"FRV1K",1130580001.101,"46,7",8) +B +"FRV1K",1130580001.101,"46,7",8,1) +MU NQF0059 DM DENOM-ALL RS +"FRV1K",1130580001.101,"47,7",7) +B +"FRV1K",1130580001.101,"47,7",7,1) +MU NQF0061 NUM DM BP<140/90 RS +"FRV1K",1130580001.101,"47,7",8) +B +"FRV1K",1130580001.101,"47,7",8,1) +MU NQF0059 DM DENOM-ALL RS +"FRV1K",1130580001.101,"81,7",7) +B +"FRV1K",1130580001.101,"81,7",7,1) +MU NQF0028B TOBACCO INTERV NUM2 RS +"FRV1K",1130580001.101,"81,7",8) +B +"FRV1K",1130580001.101,"81,7",8,1) +MU NQF0028B TOBACCO INTERV DENOM RS +"FRV1K",1130580001.101,"82,7",7) +B +"FRV1K",1130580001.101,"82,7",7,1) +MU NQF0024 BMI PERCENTILE 2-10Y RS +"FRV1K",1130580001.101,"82,7",8) +B +"FRV1K",1130580001.101,"82,7",8,1) +MU NQF0024 BMI 2-10Y DENOM RS +"FRV1K",1130580001.101,"83,7",7) +B +"FRV1K",1130580001.101,"83,7",7,1) +MU NQF0038 NUM1 DPT RS +"FRV1K",1130580001.101,"83,7",8) +B +"FRV1K",1130580001.101,"83,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"83,7",9) +B +"FRV1K",1130580001.101,"83,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"84,7",7) +B +"FRV1K",1130580001.101,"84,7",7,1) +MU NQF0038 NUM2 IPV RS +"FRV1K",1130580001.101,"84,7",8) +B +"FRV1K",1130580001.101,"84,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"84,7",9) +B +"FRV1K",1130580001.101,"84,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"85,7",7) +B +"FRV1K",1130580001.101,"85,7",7,1) +MU NQF0038 NUM3-ALL RS +"FRV1K",1130580001.101,"85,7",8) +B +"FRV1K",1130580001.101,"85,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"85,7",9) +B +"FRV1K",1130580001.101,"85,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"86,7",7) +B +"FRV1K",1130580001.101,"86,7",7,1) +MU NQF0038 NUM4 HIB RS +"FRV1K",1130580001.101,"86,7",8) +B +"FRV1K",1130580001.101,"86,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"86,7",9) +B +"FRV1K",1130580001.101,"86,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"87,7",7) +B +"FRV1K",1130580001.101,"87,7",7,1) +MU NQF0038 NUM5 RS +"FRV1K",1130580001.101,"87,7",8) +B +"FRV1K",1130580001.101,"87,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"87,7",9) +B +"FRV1K",1130580001.101,"87,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"88,7",7) +B +"FRV1K",1130580001.101,"88,7",7,1) +MU NQF0038 NUM6 VZV RS +"FRV1K",1130580001.101,"88,7",8) +B +"FRV1K",1130580001.101,"88,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"88,7",9) +B +"FRV1K",1130580001.101,"88,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"89,7",7) +B +"FRV1K",1130580001.101,"89,7",7,1) +MU NQF0038 NUM7 PCV RS +"FRV1K",1130580001.101,"89,7",8) +B +"FRV1K",1130580001.101,"89,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"89,7",9) +B +"FRV1K",1130580001.101,"89,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"90,7",7) +B +"FRV1K",1130580001.101,"90,7",7,1) +MU NQF0038 NUM8 HEP A RS +"FRV1K",1130580001.101,"90,7",8) +B +"FRV1K",1130580001.101,"90,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"90,7",9) +B +"FRV1K",1130580001.101,"90,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"91,7",7) +B +"FRV1K",1130580001.101,"91,7",7,1) +MU NQF0038 NUM9 RV RS +"FRV1K",1130580001.101,"91,7",8) +B +"FRV1K",1130580001.101,"91,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"91,7",9) +B +"FRV1K",1130580001.101,"91,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"92,7",7) +B +"FRV1K",1130580001.101,"92,7",7,1) +MU NQF0038 NUM10 INFLUENZA RS +"FRV1K",1130580001.101,"92,7",8) +B +"FRV1K",1130580001.101,"92,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"92,7",9) +B +"FRV1K",1130580001.101,"92,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"93,7",7) +B +"FRV1K",1130580001.101,"93,7",7,1) +MU NQF0038 NUM11 COMBO5 RS +"FRV1K",1130580001.101,"93,7",8) +B +"FRV1K",1130580001.101,"93,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"93,7",9) +B +"FRV1K",1130580001.101,"93,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"FRV1K",1130580001.101,"94,7",7) +B +"FRV1K",1130580001.101,"94,7",7,1) +MU NQF0038 NUM12 COMBO6 RS +"FRV1K",1130580001.101,"94,7",8) +B +"FRV1K",1130580001.101,"94,7",8,1) +MU NQF0038 DENOM RS +"FRV1K",1130580001.101,"94,7",9) +B +"FRV1K",1130580001.101,"94,7",9,1) +MU NQF0038 CHILDREN'S IMMUNIZATIONS +"IX",1130580001.101,1130580001.101,"MU",0) +1130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS +"IX",1130580001.101,1130580001.101,"MU",1) +S ^C0Q(101,"MU",$E(X,1,30),DA)="" +"IX",1130580001.101,1130580001.101,"MU",2) +K ^C0Q(101,"MU",$E(X,1,30),DA) +"IX",1130580001.101,1130580001.101,"MU",2.5) +K ^C0Q(101,"MU") +"IX",1130580001.101,1130580001.101,"MU",11.1,0) +^.114IA^1^1 +"IX",1130580001.101,1130580001.101,"MU",11.1,1,0) +1^F^1130580001.101^.3^30^1^F +"MBREQ") +0 +"PGL",1130580001.101,0,2,1) +NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q +"PGL",1130580001.101,0,3,2) +DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q +"PGL",1130580001.101,7,2,1.1) +ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q +"PGL",1130580001.101,7,3,2.1) +ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q +"PGL",1130580001.101,7,4,1.5) +NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q +"PGL",1130580001.101,7,5,1.51) +ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q +"PGL",1130580001.101,7,7,1.2) +NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X +"PGL",1130580001.101,7,8,2.2) +DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X +"PGL",1130580001.101,7,9,2.5) +EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q +"PKG",215,-1) +1^1 +"PKG",215,0) +QUALITY MEASURES^C0Q^Tracks and Prints Quality Measures +"PKG",215,20,0) +^9.402P^^ +"PKG",215,22,0) +^9.49I^1^1 +"PKG",215,22,1,0) +1.0^3120731^3120802^8 +"PKG",215,22,1,"PAH",1,0) +3^3120803 +"PKG",215,22,1,"PAH",1,1,0) +^^155^155^3120803 +"PKG",215,22,1,"PAH",1,1,1,0) + Summary +"PKG",215,22,1,"PAH",1,1,2,0) + ======= +"PKG",215,22,1,"PAH",1,1,3,0) + This build contains the Quality Measures file (#1130580001.101) fully +"PKG",215,22,1,"PAH",1,1,4,0) + populated with the Reminder Rule Sets and if applicable Reminder Extract +"PKG",215,22,1,"PAH",1,1,5,0) + definitions for use with the Quality Measures package for reporting for +"PKG",215,22,1,"PAH",1,1,6,0) + Meaningful use Stage I. +"PKG",215,22,1,"PAH",1,1,7,0) + +"PKG",215,22,1,"PAH",1,1,8,0) + Source, Copyright, & Licensing: +"PKG",215,22,1,"PAH",1,1,9,0) + =============================== +"PKG",215,22,1,"PAH",1,1,10,0) + This patch to WorldVistA 2.0 was produced by Sam Habiel on a copy of Dew +"PKG",215,22,1,"PAH",1,1,11,0) +Drop and tested on a virgin instance of WV EHR 3-09 patched with PXRM 2.0 +"PKG",215,22,1,"PAH",1,1,12,0) +patches 12 and 17. The build was produced in July 2012. +"PKG",215,22,1,"PAH",1,1,13,0) + Copyright WorldVistA 2012. +"PKG",215,22,1,"PAH",1,1,14,0) + Licensed under GPL version 2 or later. Find it here: +"PKG",215,22,1,"PAH",1,1,15,0) +http://www.gnu.org/licenses/gpl-2.0.html +"PKG",215,22,1,"PAH",1,1,16,0) + Released through VISTA Forum. +"PKG",215,22,1,"PAH",1,1,17,0) + +"PKG",215,22,1,"PAH",1,1,18,0) + Functionality: +"PKG",215,22,1,"PAH",1,1,19,0) + ============== +"PKG",215,22,1,"PAH",1,1,20,0) + This patch is a pure data patch. It only installs reference data in the +"PKG",215,22,1,"PAH",1,1,21,0) +C0Q QUALITY MEASURE file (#1130580001.101). It relies on Reminder Package +"PKG",215,22,1,"PAH",1,1,22,0) +data (specifically rule sets and extracts) sent in C0Q*1.0*2. +"PKG",215,22,1,"PAH",1,1,23,0) + +"PKG",215,22,1,"PAH",1,1,24,0) + Package Elements: +"PKG",215,22,1,"PAH",1,1,25,0) + ================= +"PKG",215,22,1,"PAH",1,1,26,0) + This build transports entries in the C0Q QUALITY MEASURE file. +"PKG",215,22,1,"PAH",1,1,27,0) + +"PKG",215,22,1,"PAH",1,1,28,0) + Routines: +"PKG",215,22,1,"PAH",1,1,29,0) + ========= +"PKG",215,22,1,"PAH",1,1,30,0) + +"PKG",215,22,1,"PAH",1,1,31,0) + +"PKG",215,22,1,"PAH",1,1,32,0) + Documentation: +"PKG",215,22,1,"PAH",1,1,33,0) + +"PKG",215,22,1,"PAH",1,1,34,0) + +"PKG",215,22,1,"PAH",1,1,35,0) + Test Sites: +"PKG",215,22,1,"PAH",1,1,36,0) + =========== +"PKG",215,22,1,"PAH",1,1,37,0) + +"PKG",215,22,1,"PAH",1,1,38,0) + +"PKG",215,22,1,"PAH",1,1,39,0) + Compliance: +"PKG",215,22,1,"PAH",1,1,40,0) + =========== +"PKG",215,22,1,"PAH",1,1,41,0) + This software complies with the VA MUMPS Programming Standards and +"PKG",215,22,1,"PAH",1,1,42,0) + Conventions (version 3 April 2007). +"PKG",215,22,1,"PAH",1,1,43,0) + +"PKG",215,22,1,"PAH",1,1,44,0) + Installation Instructions: +"PKG",215,22,1,"PAH",1,1,45,0) + ========================== +"PKG",215,22,1,"PAH",1,1,46,0) + Pre-installation: +"PKG",215,22,1,"PAH",1,1,47,0) + +"PKG",215,22,1,"PAH",1,1,48,0) + Prerequisite patches: (both found on the trac server here: +"PKG",215,22,1,"PAH",1,1,49,0) + https://trac.opensourcevista.net/svn/qrda/C0Q/trunk/kids/) +"PKG",215,22,1,"PAH",1,1,50,0) + C0Q*1.0*2 +"PKG",215,22,1,"PAH",1,1,51,0) + QUALITY MEASURES 1.0 +"PKG",215,22,1,"PAH",1,1,52,0) + +"PKG",215,22,1,"PAH",1,1,53,0) + Users can remain on the system while this patch is installed. +"PKG",215,22,1,"PAH",1,1,54,0) + +"PKG",215,22,1,"PAH",1,1,55,0) + Install Time - less than 1 minute. +"PKG",215,22,1,"PAH",1,1,56,0) + +"PKG",215,22,1,"PAH",1,1,57,0) + 1. LOAD TRANSPORT GLOBAL +"PKG",215,22,1,"PAH",1,1,58,0) + +"PKG",215,22,1,"PAH",1,1,59,0) + Choose the PackMan message containing this patch and invoke the +"PKG",215,22,1,"PAH",1,1,60,0) + INSTALL/CHECK MESSAGE PackMan option to unload the build, or +"PKG",215,22,1,"PAH",1,1,61,0) + Use the Load a Distribution option in KIDS to load it from a +"PKG",215,22,1,"PAH",1,1,62,0) + host file. +"PKG",215,22,1,"PAH",1,1,63,0) + +"PKG",215,22,1,"PAH",1,1,64,0) + 2. START UP KIDS +"PKG",215,22,1,"PAH",1,1,65,0) + +"PKG",215,22,1,"PAH",1,1,66,0) + Start up the Kernel Installation and Distribution System Menu +"PKG",215,22,1,"PAH",1,1,67,0) + [XPD MAIN]: +"PKG",215,22,1,"PAH",1,1,68,0) + +"PKG",215,22,1,"PAH",1,1,69,0) + Edits and Distribution ... +"PKG",215,22,1,"PAH",1,1,70,0) + Utilities ... +"PKG",215,22,1,"PAH",1,1,71,0) + Installation ... +"PKG",215,22,1,"PAH",1,1,72,0) + +"PKG",215,22,1,"PAH",1,1,73,0) + Select Kernel Installation & Distribution System Option: INStallation +"PKG",215,22,1,"PAH",1,1,74,0) + --- +"PKG",215,22,1,"PAH",1,1,75,0) + Load a Distribution +"PKG",215,22,1,"PAH",1,1,76,0) + Print Transport Global +"PKG",215,22,1,"PAH",1,1,77,0) + Compare Transport Global to Current System +"PKG",215,22,1,"PAH",1,1,78,0) + Verify Checksums in Transport Global +"PKG",215,22,1,"PAH",1,1,79,0) + Install Package(s) +"PKG",215,22,1,"PAH",1,1,80,0) + Restart Install of Package(s) +"PKG",215,22,1,"PAH",1,1,81,0) + Unload a Distribution +"PKG",215,22,1,"PAH",1,1,82,0) + Backup a Transport Global +"PKG",215,22,1,"PAH",1,1,83,0) + +"PKG",215,22,1,"PAH",1,1,84,0) + Select Installation Option: +"PKG",215,22,1,"PAH",1,1,85,0) + +"PKG",215,22,1,"PAH",1,1,86,0) + 3. Select Installation Option: +"PKG",215,22,1,"PAH",1,1,87,0) + +"PKG",215,22,1,"PAH",1,1,88,0) + NOTE: The following are OPTIONAL - (When prompted for the INSTALL +"PKG",215,22,1,"PAH",1,1,89,0) + NAME, enter C0Q*1.0*3): +"PKG",215,22,1,"PAH",1,1,90,0) + +"PKG",215,22,1,"PAH",1,1,91,0) + a. Backup a Transport Global - This option will create a backup +"PKG",215,22,1,"PAH",1,1,92,0) + message of any routines exported with this patch. It will not +"PKG",215,22,1,"PAH",1,1,93,0) + backup any other changes such as DD's or templates. +"PKG",215,22,1,"PAH",1,1,94,0) + b. Compare Transport Global to Current System - This option will +"PKG",215,22,1,"PAH",1,1,95,0) + allow you to view all changes that will be made when this patch +"PKG",215,22,1,"PAH",1,1,96,0) + is installed. It compares all components of this patch +"PKG",215,22,1,"PAH",1,1,97,0) + (routines, DD's, templates, etc.). +"PKG",215,22,1,"PAH",1,1,98,0) + c. Verify Checksums in Transport Global - This option will allow +"PKG",215,22,1,"PAH",1,1,99,0) + you to ensure the integrity of the routines that are in the +"PKG",215,22,1,"PAH",1,1,100,0) + transport global. +"PKG",215,22,1,"PAH",1,1,101,0) + +"PKG",215,22,1,"PAH",1,1,102,0) + 4. Select Installation Option: Install Package(s) +"PKG",215,22,1,"PAH",1,1,103,0) + +"PKG",215,22,1,"PAH",1,1,104,0) + **This is the step to start the installation of this KIDS patch: +"PKG",215,22,1,"PAH",1,1,105,0) + +"PKG",215,22,1,"PAH",1,1,106,0) + a. Choose the Install Package(s) option to start the patch install +"PKG",215,22,1,"PAH",1,1,107,0) + and enter "C0Q*1.0*3" at the INSTALL NAME prompt. +"PKG",215,22,1,"PAH",1,1,108,0) + b. When prompted 'Want KIDS to Rebuild Menu Trees Upon Completion of +"PKG",215,22,1,"PAH",1,1,109,0) + Install? NO//' answer NO +"PKG",215,22,1,"PAH",1,1,110,0) + c. When prompted 'Want KIDS to INHIBIT LOGONs during the install? +"PKG",215,22,1,"PAH",1,1,111,0) + NO//' answer NO +"PKG",215,22,1,"PAH",1,1,112,0) + d. When prompted 'Want to DISABLE Scheduled Options, Menu Options, +"PKG",215,22,1,"PAH",1,1,113,0) + and Protocols? NO//' answer NO +"PKG",215,22,1,"PAH",1,1,114,0) + +"PKG",215,22,1,"PAH",1,1,115,0) + +"PKG",215,22,1,"PAH",1,1,116,0) +Here is an example installation log. +"PKG",215,22,1,"PAH",1,1,117,0) +Select INSTALL NAME: C0Q*1.0*3 Loaded from Distribution Loaded +"PKG",215,22,1,"PAH",1,1,118,0) +from Di +"PKG",215,22,1,"PAH",1,1,119,0) +stribution 8/3/12@16:32:30 +"PKG",215,22,1,"PAH",1,1,120,0) + => SDFGHJKL ;Created on Aug 03, 2012@16:31:28 +"PKG",215,22,1,"PAH",1,1,121,0) + +"PKG",215,22,1,"PAH",1,1,122,0) +This Distribution was loaded on Aug 03, 2012@16:32:30 with header of +"PKG",215,22,1,"PAH",1,1,123,0) + SDFGHJKL ;Created on Aug 03, 2012@16:31:28 +"PKG",215,22,1,"PAH",1,1,124,0) + It consisted of the following Install(s): +"PKG",215,22,1,"PAH",1,1,125,0) + C0Q*1.0*3 +"PKG",215,22,1,"PAH",1,1,126,0) + +"PKG",215,22,1,"PAH",1,1,127,0) + Checking C0Q*1.0*3 for overlap with VOE 1.0 . OK +"PKG",215,22,1,"PAH",1,1,128,0) + No overlap found +"PKG",215,22,1,"PAH",1,1,129,0) +DEVICE: HOME// PHOME HOME PRINTER +"PKG",215,22,1,"PAH",1,1,130,0) + +"PKG",215,22,1,"PAH",1,1,131,0) + +"PKG",215,22,1,"PAH",1,1,132,0) + Install Started for C0Q*1.0*3 : +"PKG",215,22,1,"PAH",1,1,133,0) + Aug 03, 2012@16:35:24 +"PKG",215,22,1,"PAH",1,1,134,0) + +"PKG",215,22,1,"PAH",1,1,135,0) +Build Distribution Date: Aug 03, 2012 +"PKG",215,22,1,"PAH",1,1,136,0) + +"PKG",215,22,1,"PAH",1,1,137,0) + Installing Routines:. +"PKG",215,22,1,"PAH",1,1,138,0) + Aug 03, 2012@16:35:24 +"PKG",215,22,1,"PAH",1,1,139,0) + +"PKG",215,22,1,"PAH",1,1,140,0) + Installing Data Dictionaries: .. +"PKG",215,22,1,"PAH",1,1,141,0) + Aug 03, 2012@16:35:24 +"PKG",215,22,1,"PAH",1,1,142,0) + +"PKG",215,22,1,"PAH",1,1,143,0) + Installing Data: +"PKG",215,22,1,"PAH",1,1,144,0) + Aug 03, 2012@16:35:24 +"PKG",215,22,1,"PAH",1,1,145,0) + +"PKG",215,22,1,"PAH",1,1,146,0) + Updating Routine file..... +"PKG",215,22,1,"PAH",1,1,147,0) + +"PKG",215,22,1,"PAH",1,1,148,0) + Updating KIDS files....... +"PKG",215,22,1,"PAH",1,1,149,0) + +"PKG",215,22,1,"PAH",1,1,150,0) + C0Q*1.0*3 Installed. +"PKG",215,22,1,"PAH",1,1,151,0) + Aug 03, 2012@16:35:24 +"PKG",215,22,1,"PAH",1,1,152,0) + +"PKG",215,22,1,"PAH",1,1,153,0) + Not a VA primary domain +"PKG",215,22,1,"PAH",1,1,154,0) + +"PKG",215,22,1,"PAH",1,1,155,0) + NO Install Message sent +"QUES","XPF1",0) +Y +"QUES","XPF1","??") +^D REP^XPDH +"QUES","XPF1","A") +Shall I write over your |FLAG| File +"QUES","XPF1","B") +YES +"QUES","XPF1","M") +D XPF1^XPDIQ +"QUES","XPF2",0) +Y +"QUES","XPF2","??") +^D DTA^XPDH +"QUES","XPF2","A") +Want my data |FLAG| yours +"QUES","XPF2","B") +YES +"QUES","XPF2","M") +D XPF2^XPDIQ +"QUES","XPI1",0) +YO +"QUES","XPI1","??") +^D INHIBIT^XPDH +"QUES","XPI1","A") +Want KIDS to INHIBIT LOGONs during the install +"QUES","XPI1","B") +NO +"QUES","XPI1","M") +D XPI1^XPDIQ +"QUES","XPM1",0) +PO^VA(200,:EM +"QUES","XPM1","??") +^D MG^XPDH +"QUES","XPM1","A") +Enter the Coordinator for Mail Group '|FLAG|' +"QUES","XPM1","B") + +"QUES","XPM1","M") +D XPM1^XPDIQ +"QUES","XPO1",0) +Y +"QUES","XPO1","??") +^D MENU^XPDH +"QUES","XPO1","A") +Want KIDS to Rebuild Menu Trees Upon Completion of Install +"QUES","XPO1","B") +NO +"QUES","XPO1","M") +D XPO1^XPDIQ +"QUES","XPZ1",0) +Y +"QUES","XPZ1","??") +^D OPT^XPDH +"QUES","XPZ1","A") +Want to DISABLE Scheduled Options, Menu Options, and Protocols +"QUES","XPZ1","B") +NO +"QUES","XPZ1","M") +D XPZ1^XPDIQ +"QUES","XPZ2",0) +Y +"QUES","XPZ2","??") +^D RTN^XPDH +"QUES","XPZ2","A") +Want to MOVE routines to other CPUs +"QUES","XPZ2","B") +NO +"QUES","XPZ2","M") +D XPZ2^XPDIQ +"SEC","^DD",1130580001.101,1130580001.101,3.1,9) + +"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT") +@ +"SEC","^DIC",1130580001.101,1130580001.101,0,"DD") +@ +"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL") +@ +"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO") +@ +"SEC","^DIC",1130580001.101,1130580001.101,0,"RD") +@ +"SEC","^DIC",1130580001.101,1130580001.101,0,"WR") +@ +"VER") +8.0^22.0 +"^DD",1130580001.101,1130580001.101,0) +FIELD^^.3^18 +"^DD",1130580001.101,1130580001.101,0,"DDA") +N +"^DD",1130580001.101,1130580001.101,0,"DT") +3111201 +"^DD",1130580001.101,1130580001.101,0,"ID",.7) +W:$D(^(5)) " ",$P(^(5),U,1) +"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01) + +"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE") + +"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01) + +"^DD",1130580001.101,1130580001.101,0,"VRPK") +QUALITY MEASURES +"^DD",1130580001.101,1130580001.101,.01,0) +NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X +"^DD",1130580001.101,1130580001.101,.01,.1) +MEASURE NAME +"^DD",1130580001.101,1130580001.101,.01,1,0) +^.1 +"^DD",1130580001.101,1130580001.101,.01,1,1,0) +1130580001.101^B +"^DD",1130580001.101,1130580001.101,.01,1,1,1) +S ^C0Q(101,"B",$E(X,1,30),DA)="" +"^DD",1130580001.101,1130580001.101,.01,1,1,2) +K ^C0Q(101,"B",$E(X,1,30),DA) +"^DD",1130580001.101,1130580001.101,.01,3) +Answer must be 1-30 characters in length +"^DD",1130580001.101,1130580001.101,.01,"DT") +3101012 +"^DD",1130580001.101,1130580001.101,.3,0) +MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X +"^DD",1130580001.101,1130580001.101,.3,.1) +MEANINGFUL USE YEAR KEY +"^DD",1130580001.101,1130580001.101,.3,3) +Answer must be 1-30 characters in length. +"^DD",1130580001.101,1130580001.101,.3,"DT") +3111201 +"^DD",1130580001.101,1130580001.101,.5,0) +TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X +"^DD",1130580001.101,1130580001.101,.5,.1) +MEASURE TITLE +"^DD",1130580001.101,1130580001.101,.5,3) +Answer must be 3-240 characters in length +"^DD",1130580001.101,1130580001.101,.5,"DT") +3110430 +"^DD",1130580001.101,1130580001.101,.61,0) +VERY LONG DESCRIPTION^1130580001.111^^6;0 +"^DD",1130580001.101,1130580001.101,.7,0) +DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X +"^DD",1130580001.101,1130580001.101,.7,.1) +QRDA DISPLAY NAME +"^DD",1130580001.101,1130580001.101,.7,3) +Answer must be 3-240 characters in length +"^DD",1130580001.101,1130580001.101,.7,"DT") +3101012 +"^DD",1130580001.101,1130580001.101,.8,0) +REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X +"^DD",1130580001.101,1130580001.101,.8,.1) +REPORTING MEASURE NAME +"^DD",1130580001.101,1130580001.101,.8,3) +Answer must be 3-30 characters in length +"^DD",1130580001.101,1130580001.101,.8,"DT") +3110615 +"^DD",1130580001.101,1130580001.101,1,0) +NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q +"^DD",1130580001.101,1130580001.101,1,.1) +MEASURE NUMERATOR PATIENT LIST +"^DD",1130580001.101,1130580001.101,1,"DT") +3101012 +"^DD",1130580001.101,1130580001.101,1.1,0) +ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q +"^DD",1130580001.101,1130580001.101,1.1,"DT") +3110805 +"^DD",1130580001.101,1130580001.101,1.2,0) +NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X +"^DD",1130580001.101,1130580001.101,1.2,3) +Enter the reminder rule set to use for this measure. +"^DD",1130580001.101,1130580001.101,1.2,12) +If the type of the reminder list rule is a Rule Set. +"^DD",1130580001.101,1130580001.101,1.2,12.1) +S DIC("S")="I $P(^(0),U,3)=3" +"^DD",1130580001.101,1130580001.101,1.2,21,0) +^^5^5^3120716^ +"^DD",1130580001.101,1130580001.101,1.2,21,1,0) +This is the numerator reminder rule set to use for the quality measure. +"^DD",1130580001.101,1130580001.101,1.2,21,2,0) + +"^DD",1130580001.101,1130580001.101,1.2,21,3,0) +The rule set is used to generate a patient list, which this package +"^DD",1130580001.101,1130580001.101,1.2,21,4,0) +referneces. The contents of the patient list will produce the count for +"^DD",1130580001.101,1130580001.101,1.2,21,5,0) +the measure. This count is for the numerator. +"^DD",1130580001.101,1130580001.101,1.2,"DT") +3120716 +"^DD",1130580001.101,1130580001.101,1.5,0) +NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q +"^DD",1130580001.101,1130580001.101,1.5,.1) +LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS +"^DD",1130580001.101,1130580001.101,1.5,"DT") +3110809 +"^DD",1130580001.101,1130580001.101,1.51,0) +ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q +"^DD",1130580001.101,1130580001.101,1.51,.1) +NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE +"^DD",1130580001.101,1130580001.101,1.51,"DT") +3110809 +"^DD",1130580001.101,1130580001.101,2,0) +DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q +"^DD",1130580001.101,1130580001.101,2,.1) +MEASURE DENOMINATOR PATIENT LIST +"^DD",1130580001.101,1130580001.101,2,"DT") +3101012 +"^DD",1130580001.101,1130580001.101,2.1,0) +ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q +"^DD",1130580001.101,1130580001.101,2.1,"DT") +3110805 +"^DD",1130580001.101,1130580001.101,2.2,0) +DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X +"^DD",1130580001.101,1130580001.101,2.2,3) +Enter the reminder rule set to use for this measure. +"^DD",1130580001.101,1130580001.101,2.2,12) +If the type of the reminder list rule is a Rule Set. +"^DD",1130580001.101,1130580001.101,2.2,12.1) +S DIC("S")="I $P(^(0),U,3)=3" +"^DD",1130580001.101,1130580001.101,2.2,21,0) +^^5^5^3120716^ +"^DD",1130580001.101,1130580001.101,2.2,21,1,0) +This is the denominator reminder rule set to use for the quality measure. +"^DD",1130580001.101,1130580001.101,2.2,21,2,0) + +"^DD",1130580001.101,1130580001.101,2.2,21,3,0) +The rule set is used to generate a patient list, which this package +"^DD",1130580001.101,1130580001.101,2.2,21,4,0) +referneces. The contents of the patient list will produce the count for +"^DD",1130580001.101,1130580001.101,2.2,21,5,0) +the measure. This count is for the denominator. +"^DD",1130580001.101,1130580001.101,2.2,"DT") +3120716 +"^DD",1130580001.101,1130580001.101,2.5,0) +EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q +"^DD",1130580001.101,1130580001.101,2.5,3) +Select a Reminder Extract Definition for this measure +"^DD",1130580001.101,1130580001.101,2.5,21,0) +^^4^4^3120726^ +"^DD",1130580001.101,1130580001.101,2.5,21,1,0) +If this measure depends upon a reminder extract definition, you can add +"^DD",1130580001.101,1130580001.101,2.5,21,2,0) +this extract definition here. This will alter how the Quality Measures +"^DD",1130580001.101,1130580001.101,2.5,21,3,0) +package computes the measure to use the extract in addition and prior to +"^DD",1130580001.101,1130580001.101,2.5,21,4,0) +the rule sets. +"^DD",1130580001.101,1130580001.101,2.5,"DT") +3120726 +"^DD",1130580001.101,1130580001.101,3,0) +QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X +"^DD",1130580001.101,1130580001.101,3,.1) +MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT +"^DD",1130580001.101,1130580001.101,3,3) +Answer must be 3-120 characters in length +"^DD",1130580001.101,1130580001.101,3,"DT") +3101012 +"^DD",1130580001.101,1130580001.101,3.1,0) +QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12" +"^DD",1130580001.101,1130580001.101,3.1,.1) +QRDA SYSTEM OID (FIXED) +"^DD",1130580001.101,1130580001.101,3.1,9.01) + +"^DD",1130580001.101,1130580001.101,3.1,9.1) +S X="2.16.840.1.113883.3.249.12" +"^DD",1130580001.101,1130580001.101,3.1,"DT") +3101012 +"^DD",1130580001.101,1130580001.101,3.2,0) +QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X +"^DD",1130580001.101,1130580001.101,3.2,.1) +QRDA MEASURE CODE +"^DD",1130580001.101,1130580001.101,3.2,3) +Answer must be 1-80 characters in length +"^DD",1130580001.101,1130580001.101,3.2,"DT") +3101012 +"^DD",1130580001.101,1130580001.111,0) +VERY LONG DESCRIPTION SUB-FIELD^^.01^1 +"^DD",1130580001.101,1130580001.111,0,"DT") +3101013 +"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION") + +"^DD",1130580001.101,1130580001.111,0,"UP") +1130580001.101 +"^DD",1130580001.101,1130580001.111,.01,0) +VERY LONG DESCRIPTION^Wx^^0;1 +"^DD",1130580001.101,1130580001.111,.01,.1) +LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6 +"^DD",1130580001.101,1130580001.111,.01,3) +LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION +"^DD",1130580001.101,1130580001.111,.01,"DT") +3101013 +"^DIC",1130580001.101,1130580001.101,0) +C0Q QUALITY MEASURE^1130580001.101 +"^DIC",1130580001.101,1130580001.101,0,"GL") +^C0Q(101, +"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101) + +**END** +**END** Index: /qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.TXT =================================================================== --- /qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.TXT (revision 1508) +++ /qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.TXT (revision 1508) @@ -0,0 +1,201 @@ +TYPE: SINGLE PACKAGE TRACK NATIONALLY: YES +NATIONAL PACKAGE: QUALITY MEASURES ALPHA/BETA TESTING: NO + + Summary + ======= + This build contains the Quality Measures file (#1130580001.101) fully + populated with the Reminder Rule Sets and if applicable Reminder Extract + definitions for use with the Quality Measures package for reporting for + Meaningful use Stage I. + + Source, Copyright, & Licensing: + =============================== + This patch to WorldVistA 2.0 was produced by Sam Habiel on a copy of Dew +Drop and tested on a virgin instance of WV EHR 3-09 patched with PXRM 2.0 +patches 12 and 17. The build was produced in July 2012. + Copyright WorldVistA 2012. + Licensed under GPL version 2 or later. Find it here: +http://www.gnu.org/licenses/gpl-2.0.html + Released through VISTA Forum. + + Functionality: + ============== + This patch is a pure data patch. It only installs reference data in the C0Q + QUALITY MEASURE file (#1130580001.101). It relies on Reminder Package data + (specifically rule sets and extracts) sent in C0Q*1.0*2. + + Package Elements: + ================= + This build transports entries in the C0Q QUALITY MEASURE file. + + Routines: + ========= + + + Documentation: + + + Test Sites: + =========== + + + Compliance: + =========== + This software complies with the VA MUMPS Programming Standards and + Conventions (version 3 April 2007). + + Installation Instructions: + ========================== + Pre-installation: + + Prerequisite patches: (both found on the trac server here: + https://trac.opensourcevista.net/svn/qrda/C0Q/trunk/kids/) + C0Q*1.0*2 + QUALITY MEASURES 1.0 + + Users can remain on the system while this patch is installed. + + Install Time - less than 1 minute. + + 1. LOAD TRANSPORT GLOBAL + + Choose the PackMan message containing this patch and invoke the + INSTALL/CHECK MESSAGE PackMan option to unload the build, or + Use the Load a Distribution option in KIDS to load it from a + host file. + + 2. START UP KIDS + + Start up the Kernel Installation and Distribution System Menu + [XPD MAIN]: + + Edits and Distribution ... + Utilities ... + Installation ... + + Select Kernel Installation & Distribution System Option: INStallation + --- + Load a Distribution + Print Transport Global + Compare Transport Global to Current System + Verify Checksums in Transport Global + Install Package(s) + Restart Install of Package(s) + Unload a Distribution + Backup a Transport Global + + Select Installation Option: + + 3. Select Installation Option: + + NOTE: The following are OPTIONAL - (When prompted for the INSTALL + NAME, enter C0Q*1.0*3): + + a. Backup a Transport Global - This option will create a backup + message of any routines exported with this patch. It will not + backup any other changes such as DD's or templates. + b. Compare Transport Global to Current System - This option will + allow you to view all changes that will be made when this patch + is installed. It compares all components of this patch + (routines, DD's, templates, etc.). + c. Verify Checksums in Transport Global - This option will allow + you to ensure the integrity of the routines that are in the + transport global. + + 4. Select Installation Option: Install Package(s) + + **This is the step to start the installation of this KIDS patch: + + a. Choose the Install Package(s) option to start the patch install + and enter "C0Q*1.0*3" at the INSTALL NAME prompt. + b. When prompted 'Want KIDS to Rebuild Menu Trees Upon Completion of + Install? NO//' answer NO + c. When prompted 'Want KIDS to INHIBIT LOGONs during the install? + NO//' answer NO + d. When prompted 'Want to DISABLE Scheduled Options, Menu Options, + and Protocols? NO//' answer NO + + +Here is an example installation log. +Select INSTALL NAME: C0Q*1.0*3 Loaded from Distribution Loaded from Di +stribution 8/3/12@16:32:30 + => SDFGHJKL ;Created on Aug 03, 2012@16:31:28 + +This Distribution was loaded on Aug 03, 2012@16:32:30 with header of + SDFGHJKL ;Created on Aug 03, 2012@16:31:28 + It consisted of the following Install(s): + C0Q*1.0*3 + + Checking C0Q*1.0*3 for overlap with VOE 1.0 . OK + No overlap found + + + Checking C0Q*1.0*3 for overlap with VOE 1.1 . OK + No overlap found + + + Checking C0Q*1.0*3 for overlap with NO HOME 1.0 . OK + No overlap found + +Checking Install for Package C0Q*1.0*3 + +Install Questions for C0Q*1.0*3 + +Incoming Files: + + + 1130580001.101C0Q QUALITY MEASURE (including data) +Note: You already have the 'C0Q QUALITY MEASURE' File. +I will OVERWRITE your data with mine. + + +Want KIDS to INHIBIT LOGONs during the install? NO// +Want to DISABLE Scheduled Options, Menu Options, and Protocols? NO// + +Enter the Device you want to print the Install messages. +You can queue the install by enter a 'Q' at the device prompt. +Enter a '^' to abort the install. + +DEVICE: HOME// PHOME HOME PRINTER + + + Install Started for C0Q*1.0*3 : + Aug 03, 2012@16:35:24 + +Build Distribution Date: Aug 03, 2012 + + Installing Routines:. + Aug 03, 2012@16:35:24 + + Installing Data Dictionaries: .. + Aug 03, 2012@16:35:24 + + Installing Data: + Aug 03, 2012@16:35:24 + + Updating Routine file..... + + Updating KIDS files....... + + C0Q*1.0*3 Installed. + Aug 03, 2012@16:35:24 + + Not a VA primary domain + + NO Install Message sent + +ENVIRONMENT CHECK: DELETE ENV ROUTINE: + PRE-INIT ROUTINE: DELETE PRE-INIT ROUTINE: +POST-INIT ROUTINE: DELETE POST-INIT ROUTINE: +PRE-TRANSPORT RTN: + + UP SEND DATA USER + DATE SEC. COMES SITE RSLV OVER +FILE # FILE NAME DD CODE W/FILE DATA PTRS RIDE +------------------------------------------------------------------------------- + +1130580001.101C0Q QUALITY MEASURE YES YES YES OVER YES NO + +REQUIRED BUILDS: ACTION: + C0Q*1.0*2 Don't install, leave global + QUALITY MEASURES 1.0 Don't install, leave global